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 Mismatch Repair Processing of DNA Damage Causes Replication Stress 
 
Dipika Gupta 
University of Connecticut, 2018 
 
The DNA mismatch repair (MMR) pathway, a crucial post-replicative repair pathway, is essential 
to the maintenance of genomic stability. Consequentially, loss of MMR increases mutation 
frequency, promoting tumorigenesis. However, if and how MMR activity coordinates with cellular 
replication forks is unclear. Particularly, at forks encountering lesions that cannot be faithfully 
replicated, like O6-methylguanine (MeG) lesions created by DNA alkylating agents, MMR-
directed processing of resultant mismatches could disrupt fork progression. Yet the events 
following lesion recognition remain elusive. In transformed cells MMR-dependent MeG/T 
recognition in the first S phase elicits a permanent G2 arrest in the subsequent cell cycle. Yet, 
in human pluripotent stem cells (hPSCs), it activates an immediate and robust MMR-dependent 
apoptotic response. In this study, we ascertained how MeG/T lesion recognition affects the first 
S phase in human embryonic stem cells (hESCs) and transformed HeLa cells. MMR-proficient 
HeLa cells exposed to alkylation damage activated ataxia telangiectasia and Rad3-related 
(ATR)-Checkpoint Kinase 1 (Chk1) signaling, slowing progression through the first S phase. Yet, 
DNA replication is completed, and cells progress into the next cell cycle. Conversely, inhibition 
of ATR-Chk1 signaling accelerates S phase progression, damage accumulation and sensitivity 
to DNA alkylating agents. In addition, as MMR-proficient human embryonic stem cells exposed 
to alkylation damage fail to activate ATR-Chk1 signaling, MMR activity severely compromises 
DNA replication leading to accumulation of toxic double strand breaks and rapid apoptotic 
induction. We propose that MMR-directed futile repair cycles disrupt fork progression implicating 
the MMR-directed repair of alkylation damage as a replication stress inducer.  
 Dipika Gupta, University of Connecticut, 2018 
 
Thereafter, ATR-Chk1 mediated intra-S phase checkpoint activation mitigates replication stress 
and facilitates completion of replication. Absence of this signaling, however, accelerates 
damage accumulation and sensitivity to alkylating agents. This work changes how we view this 
post-replicative repair pathway, suggesting a coordination between MMR activity and the DNA 
replication machinery. In addition, these results reveal that different cell types may have different 
levels of sensitivity to MMR processing of lesions. Taken together, this work provides the 
foundation for understanding how MMR is executed at cellular replication forks and has crucial 
implications for the mechanism of MMR, early tumorigenesis, cancer prevention and 
chemotherapeutics.      
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Desiderata 
 
Go placidly amid the noise and haste, 
and remember what peace there may be in silence. 
As far as possible without surrender be on good terms with all persons. 
Speak your truth quietly and clearly; and listen to others, even the dull and the ignorant; 
they too have their story. 
Avoid loud and aggressive persons, they are vexations to the spirit. 
If you compare yourself with others, you may become vain and bitter; 
for always there will be greater and lesser persons than yourself. 
Enjoy your achievements as well as your plans. 
Keep interested in your own career, however humble; 
it is a real possession in the changing fortunes of time. 
Exercise caution in your business affairs; for the world is full of trickery. 
But let this not blind you to what virtue there is; 
many persons strive for high ideals; and everywhere life is full of heroism. 
Be yourself. 
Especially, do not feign affection. 
Neither be cynical about love; for in the face of all aridity and disenchantment 
it is as perennial as the grass. 
Take kindly the counsel of the years, 
gracefully surrendering the things of youth. 
Nurture strength of spirit to shield you in sudden misfortune. 
But do not distress yourself with dark imaginings. 
Many fears are born of fatigue and loneliness. 
Beyond a wholesome discipline, be gentle with yourself. 
You are a child of the universe, no less than the trees and the stars; 
you have a right to be here. 
And whether or not it is clear to you, no doubt the universe is unfolding as it should. 
Therefore be at peace with God, whatever you conceive Him to be, 
and whatever your labors and aspirations, 
in the noisy confusion of life keep peace with your soul. 
With all its sham, drudgery, and broken dreams, it is still a beautiful world. 
Be cheerful. 
Strive to be happy. 
- By Max Ehrmann 
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CHAPTER 1 
 
INTRODUCTION 
 
I. LYNCH SYNDROME: 
 
Lynch syndrome (LS) accounts for 2-7% of all colon cancer cases and is the most common 
form of hereditary colon cancer. Although initially described as a colon cancer predisposition 
syndrome, this syndrome confers an 80-90% risk of developing a broad spectrum of cancers 
including that of the endometrium, small bowel and pancreas (Heinen 2014, Lynch, Snyder et al. 
2015). This autosomal dominant disease is caused by the inheritance of mutations in one of four 
DNA mismatch repair (MMR) genes. Initially heterozygous for the mutant MMR gene, a 
spontaneous mutation or loss of heterozygosity event at the wild type allele confers complete loss 
of MMR function. MMR plays a crucial role in the maintenance of genomic stability. In repairing 
DNA mismatches and insertion/deletion loops (IDLs) that result during DNA replication, MMR is 
crucial to increasing DNA replication fidelity. Conversely, loss of MMR confers polymerase 
slippage events refractory to repair causing expansion or contraction of microsatellite repeat 
regions (Kunkel and Erie 2005). Consequentially, the identification of microsatellite instability 
(MSI) as a molecular phenotype characteristic to LS associated tumors in the early 1990’s 
implicated affected MMR function as the genetic cause of LS (Aaltonen, Peltomaki et al. 1993, 
Fishel, Lescoe et al. 1993, Bronner, Baker et al. 1994). Yet, the exact mechanism by which MMR 
loss contributes to tumorigenesis is unclear.  
Although, MMR fits the classical definition of a tumor suppressor, wherein both wild type 
copies must be lost for tumorigenesis, the mechanism by which MMR loss contributes to 
tumorigenesis is likely more indirect. Upon loss of MMR, DNA polymerase mistakes are made 
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permanent in the genome in the subsequent S phase. Mutation frequency increases several 
hundred-fold conferring a mutator phenotype (Kunkel and Erie 2005). The subsequent 
accumulation of mutations in tumor suppressor genes and oncogenes is predicted to be a driver 
of tumorigenesis. In addition, frameshift mutations could result from extension and contraction of 
nucleotide repeats within the coding regions of genes due to polymerase slippage causing loss 
of protein function. Particularly, in LS-related cancers these events have been identified in various 
tumor suppressor genes like adenomatous polyposis coli, proapoptotic BCL2-associated X 
protein (BAX) and transforming growth factor-β type II receptor (TGFBR2) (Duval and Hamelin 
2002, Heinen 2014, Lynch, Snyder et al. 2015). In addition, MMR protects genomic integrity by 
inducing apoptosis in response to exposure to DNA damaging agents like N-nitroso compounds. 
Although recognized as dietary carcinogens, N-nitroso compounds also arise as metabolic 
byproducts of colonic bacterial populations (Povey, Hall et al. 2000). Cells resident to these toxic 
environments likely experience an increased selection pressure to lose MMR function to bypass 
the MMR-dependent cytotoxicity of these agents, promoting survival (Heinen, Schmutte et al. 
2002). Additionally, the mutagenic nature of these agents could further contribute to 
tumorigenesis by compounding the accumulation of somatic mutations. Together, MMR loss 
could confer a selective growth advantage through the accumulation of growth promoting somatic 
mutations and/or increased resistance to DNA damaging agents.  
LS-associated colorectal cancers display certain key clinicopathological features. Cancers 
develop at early age and typically develop in the proximal colon. In addition, cancer progression 
from polyp formation to carcinoma can take as little as 2-3 years compared to the 6–10 years 
reported in sporadic cancer patients. The rapid accumulation of somatic mutations upon MMR 
loss likely contributes to this accelerated tumorigenesis phenotype. The poor differentiation of 
these tumors is characterized by mucinous features, signet ring cells and medullary cell types. 
These cancers do not display polyploidy but are positive for infiltrating T- lymphocytes and Crohn-
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Table 1-1. Bethesda Guidelines that warrant further testing for LS 
 
1. Colorectal cancer diagnosed in a patient who is ˂50 years of age 
2. Presence of synchronous or metachronous colorectal cancer or other LS-associated 
cancer, regardless of age 
3. Colorectal cancer with MSI-high histology in a patient who is ˂60 years of age  
4. Colorectal cancer or LS-associated cancer diagnosed in ≥1 first-degree relatives who 
is ˂50 years of age 
5. Colorectal cancer or LS-associated cancer diagnosed in ≥2 first- or second-degree 
relatives regardless of age 
 
Adapted from (Umar, Boland et al. 2004, Heinen 2014, Lynch, Snyder et al. 2015)  
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like lymphocytic reaction. These histological features are characteristic of tumors with high MSI. 
The Revised Bethesda guidelines, is the latest in a series of international guidelines put forth to 
identify individuals that must undergo further testing for LS (Table 1-1). However, more recently 
MSI testing and loss of MMR protein expression by immunohistochemistry are routinely used to 
screen all colon cancer patients, regardless of age and family history, to identify potential LS 
patients (Heinen 2014, Lynch, Snyder et al. 2015). As of 2015, nearly 74% of LS cases are 
associated with the inheritance of mutations in MMR genes MSH2 and MLH1 while only 18% and 
8% carry mutations in MMR genes, MSH6 and PMS2, respectively (Peltomaki 2016). 
 
II. DNA MISMATCH REPAIR 
 
i. MMR IN E.COLI 
As mentioned previously, MMR plays an essential role in increasing replication fidelity and 
the maintenance of genomic stability. Unsurprisingly, MMR is highly conserved through evolution 
and has been studied in numerous model systems. The mechanistic details of MMR are most 
completely understood in E. coli. In vitro studies utilizing engineered hemimethylated mismatch 
containing DNA substrates have identified the minimal factors essential to repair. These include 
MutS, MutL, MutH, DNA helicase II (UvrD), exonuclease I, single-strand binding (SSB) protein, 
DNA ligase, and DNA polymerase holoenzyme III (Fig. 1-1)  (Lahue, Au et al. 1989). In vitro, 
mismatches on engineered hemimethylated DNA substrates are recognized by the MutS 
homodimers which interacts with the mismatch asymmetrically (Lamers, Perrakis et al. 2000). 
The phenylalanine residue of the Phe-X-Glu motif within one of the MutS subunits inserts into and 
stacks with the mispaired bases. This is further stabilized through hydrogen bonding interactions 
with the glutamine residue (Lamers, Perrakis et al. 2000, Kunkel and Erie 2005). Mismatch 
binding triggers an ADP to ATP exchange within MutS and recruits MutL to form a ternary complex 
(Galio, Bouquet et al. 1999). A second ADP to ATP exchange within MutL promotes the interaction 
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Fig 1-1. Model of mismatch recognition by MMR proteins in E. coli  
Upon recognizing DNA mismatches, bacterial MutS homodimer recruits MutL to form a ternary 
complex. Together, they activate MutH endonuclease activity to recognize transiently hemi-
methylated GATC sites behind replication forks and nick the unmethylated strand. This creates 
an entry site for UvrD helicase and exonucleases that proceed to excise the erroneous nascent 
strand. ssDNA gaps are protected by binding of single stranded DNA binding protein SSB. DNA 
polymerase and ligase proceed to complete repair by filling and sealing the gaps. (Reproduced 
with permission from (Jiricny 2006))   
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and activation of the endonuclease activity of MutH (Ban and Yang 1998, Junop, Obmolova et al. 
2001). Once activated, MutH cleaves the GATC sequence specifically on the nascent strand. This 
strand discrimination signal is provided by the transient unmethylated state of GATC sequence 
on the nascent strand due to the lagging of the deoxyadenine methylase enzyme behind the 
replication by approximately 2 min (Langle-Rouault, Maenhaut-Michel et al. 1987, Welsh, Lu et 
al. 1987, Jiricny 2013). UvrD helicase loaded at sites of incision then proceed to unwind nascent 
strand DNA past the mismatch. SSB bind to and protect ssDNA template stretches as excision of 
the erroneous strand is accomplished by ExoI or ExoX (5’-3’exonucleases), and ExoVII or RecJ 
(3’-5’ exonucleases). DNA polymerase proceeds to fill the gap in the daughter strand. Repair is 
completed by the sealing of the remaining nick by DNA ligase (Li 2008).  
 
ii. EUKARYOTIC MMR  
An understanding of prokaryotic MMR has been crucial in informing the identification of 
eukaryotic MMR proteins. Although eukaryotic MMR has been reconstituted in vitro, differences 
in components and functions of MMR’s eukaryotic counterparts have yet to gain us a complete 
understanding of this process (Table 1-2). By assessing correction of mismatches on engineered 
heteroduplex substrates, minimal factors essential for repair have been identified. For eukaryotic 
MMR to proceed further in vitro, engineered heteroduplex substrates must contain a preexisting 
nick 3’ or 5’ to the mismatch (Fig. 1-2) (Holmes, Clark et al. 1990, Thomas, Roberts et al. 1991). 
The context of the nick in relation to the mismatch has provided key insights into the mechanism 
of MMR. Firstly, the nick provides a crucial strand discrimination signal, directing repair specifically 
to the nick containing strand. This is crucial as eukaryotic MMR does not depend on transient 
hemimethylation at d(GATC) sequences on the newly-synthesized DNA strand as a strand 
discrimination signal nor have any eukaryotic homologues of bacterial MutH been identified to 
date. In vivo, gaps generated during discontinuous synthesis of Okazaki fragments could serve 
  
7 
 
  
Table 1-2. MMR component functions in E. coli and humans 
 
Adapted from (Jiricny 2013)  
 
E. coli 
  
Eukaryotes 
 
Function 
 
MutS 
 
MSH2-MSH6 
MSH2-MSH3 
 
Mismatch recognition 
Insertion/deletion loop (IDL) recognition 
MutL MLH1-PMS2 Molecular matchmaker; strand specific 
endonuclease, termination of excision 
MutH - Strand specific endonuclease; nicks newly 
synthesized DNA at hemimethylated GATC sites 
UvrD - DNA helicase 
ExoVII, RecJ  - 3’-5’ Exonuclease for mismatch excision 
ExoI, ExoX ExoI 5’-3’ Exonuclease for mismatch excision 
Pol III holoenzyme DNA pol δ/ε. Repair synthesis 
β clamp PCNA DNA polymerase processivity factor; molecular 
matchmaker between MMR and replication fork; 
activates MLH1-PMS2 endonuclease activity for 
3’ nick directed MMR 
γ complex RFC  Loads β clamp and PCNA respectively; activates 
MLH1-PMS2 endonuclease activity for 3’ nick 
directed MMR 
SSB RPA Single-stranded DNA binding protein 
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as discrimination signals on the lagging strand. Until recently however, the sources of such strand 
discontinuities on the leading strand remained enigmatic. Interestingly, it was observed that DNA 
polymerase ε incorporates ribonucleotides into the leading strand. Gaps generated upon 
recognition and removal of these erroneous ribonucleotides lesions by RNase H2 serve as a 
source of strand discontinuities and a discrimination signal for MMR on the leading strand 
(Ghodgaonkar, Lazzaro et al. 2013, Lujan, Williams et al. 2013). Additionally, it is unknown if this 
is the only possible source of strand discontinuities on the leading strand, particularly given the 3’ 
terminus on the leading strand at the replication fork.  
Minimal factors essential to MMR in vitro differ based on the orientation of the nick relative 
to the mismatch. 5'-nick directed MMR requires the human homologue of MutS, exonuclease 1 
(EXO1), replication protein A (RPA), replication factor C (RFC), proliferating cell nuclear antigen 
(PCNA) and DNA polymerase δ/ε (Fig. 1-2) (Constantin, Dzantiev et al. 2005, Zhang, Yuan et al. 
2005, Bowen and Kolodner 2017). DNA mismatches are first recognized by the eukaryotic 
homologue of MutS. Humans express three MutS homologues involved in MMR, MSH2, MSH6 
and MSH3. Both MSH6 and MSH3 form partially redundant heterodimers with their obligate 
partner, MSH2. MSH2-MSH6 complex recognizes single base pair mismatches and 1-2 base 
insertion/deletion loops (IDLs) while MSH2-MSH3 recognizes IDLSs (Li 2008, Jiricny 2013). The 
functional asymmetry of the bacterial MutS homodimer is conserved within the MSH2-MSH6 and 
MSH2-MSH3 heterodimers. The highly conserved Phe-X-Glu motif within MSH6 interacts with 
and contacts the mismatch in a mechanism similar to that described for bacterial MutS mismatch 
recognition (Warren, Pohlhaus et al. 2007). This triggers an ADP to ATP exchange within the 
ABC-ATPase domains of both MSH2 and MSH6. Nucleotide binding, but not ATP hydrolysis, 
drives a conformational change within MSH2-MSH6 into a sliding clamp capable of diffusing along 
DNA (Gradia, Acharya et al. 1997, Gradia, Subramanian et al. 1999, Heinen, Cyr et al. 2011). 
This frees the DNA mismatch to initiate loading of additional MSH2-MSH6 clamps. DNA bound 
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MSH2-MSH6 can load the 5′ to 3′ exonuclease EXO1 onto the 5’-strand discontinuity leading to 
the excision of the nick containing strand. Although not essential to 5’-directed MMR, eukaryotic 
homologue of MutL, the MLH1-PMS2 heterodimer, is required to regulate excision by Exo1 
(Genschel, Bazemore et al. 2002). By interacting with MSH2-MSH6 complex in an ATP-
dependent manner, MLH1-PMS2 is recruited to mismatch containing DNA substrates and 
regulates Exo1 such that strand excision terminates approximately 150 nucleotides beyond the 
mismatch (Genschel, Bazemore et al. 2002, Zhang, Yuan et al. 2005). Correspondingly, Exo1 
generates large excision tracts in the absence of MLH1-PMS2. The corresponding ssDNA 
stretches are coated and protected by ssDNA binding protein, RPA. The clamp loader, RFC, loads 
the DNA polymerase processivity factor PCNA onto 3’ ends of resulting gaps. Gaps are then filled 
and sealed by DNA polymerase δ/ε and DNA ligase respectively (Longley, Pierce et al. 1997, Gu, 
Hong et al. 1998, Lin, Shivji et al. 1998).  
Understanding strand excision reactions for 3'-nick directed MMR posed a significant 
challenge as the only identified exonuclease to participate in eukaryotic MMR is the obligate 5’-3’ 
Exo 1. However, as MMR proceeded on 3'-nicked substrates, Exo 1 was suggested to have a 
cryptic 3’-5” exonuclease activity. Subsequently, the PMS2 subunit of the MLH1-PMS2 
heterodimer was identified to possess a latent endonuclease activity that is essential for 3'-nick 
directed MMR (Kadyrov, Dzantiev et al. 2006, Kadyrov, Holmes et al. 2007). After MSH2-MSH6 
dependent recruitment to heteroduplex DNA, both PCNA and RFC are required to activate the 
endonuclease activity of PMS2. Furthermore, by interacting with only one of the asymmetric ring 
faces of PCNA, loading of PCNA by RFC at 3’-ends ensures that PMS2 is oriented such that is 
only capable of incising the daughter strand (Pluciennik, Dzantiev et al. 2010). Consequentially, 
changing the orientation of PCNA loading on mismatch containing substrates dictates strand 
specificity for PMS2 nicking. MLH1-PMS2 endonuclease activity can generate nicks 5’ of the 
mismatch. Exo1 can proceed with 5’-3’ excision of the nicked strand followed by strand 
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Fig 1-2. An extrapolated prediction of the MMR mechanism at replication forks based on 
data from MMR directed repair of 5’ and 3'-nicked heteroduplex DNA substrates in-vitro. 
DNA mismatches can escape replicative polymerase proofreading on both the leading and 
lagging strands. These are recognized by eukaryotic MMR heterodimer, MSH2-MSH6, which 
recruit a second MMR heterodimer, MLH1-PMS2. Correction of mismatches on the lagging strand 
would likely parallel those observed in in vitro 5’-nick MMR reactions. Strand discontinuities 
created during Okazaki fragment synthesis could serve as entry sites for Exo1 that would proceed 
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to excise the daughter strand in the 5’-3’ direction. DNA polymerase synthesizing the preceding 
Okazaki fragment can continue to rereplicate the excised DNA fragment leading to mismatch 
correction. Alternatively, in an Exo1 independent mechanism the latent endonuclease activity of 
PMS2 is activated to generate a nick 3’ of the mismatch. DNA polymerase synthesizing the 
preceding Okazaki fragment can simultaneously rereplicate and displace the error containing 
daughter strand leading to mismatch correction. Alternatively, nicks generated by PMS2 might 
regulate Exo1 directed strand excision. Correction of mismatches on the lagging strand would 
likely parallel those observed in in vitro 3’-nick MMR reactions. Herein, the latent endonuclease 
activity of PMS2 would be essential for generating nicks on the daughter strand 5’ of the 
mismatch. This could serve as entry sites for Exo1 that can excise the daughter strand in the 5’-
3’ direction and DNA polymerase directed strand resynthesis. Alternatively in an Exo1 
independent mechanism nicks generated could initiate DNA polymerase strand resynthesis and 
simultaneous displacement of the error containing daughter strand leading to mismatch correction 
(Reproduced with permission from (Kazak, Reyes et al. 2012)).  
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resynthesis and ligation by DNA polymerase δ/ε and DNA ligase respectively. Alternatively, MMR 
can proceed via a less efficient Exo1 independent pathway wherein 5’-3’ DNA polymerase δ 
directed extension from nicks drives strand displacement and mismatch correction (Fig. 1-2) 
(Kadyrov, Genschel et al. 2009). 
 
III. DAMAGE SIGNALING:  
 
In addition to its role in removing DNA replication errors, the MMR system is also essential 
for eliciting a cytotoxic response to certain DNA damaging agents, particularly SN1 DNA alkylating 
agents (Duckett, Drummond et al. 1996, Li, Pearlman et al. 2016). This role of MMR was first 
identified in E. coli, wherein MMR loss conferred increased resistance to the SN1 DNA alkylating 
agent, N-methyl-N’-nitro-N-nitrosoguanidine (MNNG) (Karran and Marinus 1982). By the mid 
1990’s, loss of MMR in various eukaryotic systems was shown to result in 100-fold decease in 
sensitivity to MNNG (Goldmacher, Cuzick et al. 1986, Karran 2001). These results suggested that 
MMR deficient tumors might be immune to chemotherapeutic DNA methylating agents used in 
the clinic like temozolomide (Drablos, Feyzi et al. 2004, Kaina, Christmann et al. 2007).  
SN1 DNA alkylating agents create a spectrum of DNA damage that is counteracted and 
repaired by different repair pathways, like base excision repair, nucleotide excision repair, 
homologous recombination (HR) and non-homologous end joining (NHEJ)  (Fu, Calvo et al. 
2012). However, MMR-dependent cytotoxicity is elicited in response to mutagenic MeG adducts, 
that account for just 7% of lesions formed (Beranek 1990, Wyatt and Pittman 2006). An 
endogenous repair enzyme methylguanine methyl transferase (MGMT) is the first line of defense 
against these cytotoxic MeG lesions. In a suicide reaction, MGMT directs transfer of the methyl 
group onto itself which triggers MGMT inactivation and proteasomal degradation (Margison and 
Santibanez-Koref 2002, Gerson 2004, Kaina, Christmann et al. 2007). But MeG lesions that 
escape this repair are preferentially mispaired with thymidine during DNA replication (Murray 
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1987). These MeG/T mismatches are a substrate for MMR directed repair and/or signaling, which 
culminates in the elimination of these damaged cells (Fig. 1-3) (Duckett, Drummond et al. 1996, 
Kaina, Ziouta et al. 1997). Conversely, in the absence of active or functional MMR, MeG/T 
mismatches go unrecognized, resulting in the acquisition of G to A transition mutations in the 
subsequent cell cycle (Altshuler, Hodes et al. 1996). Loss of MMR therefore confers a 
"methylation tolerant" phenotype wherein the once cytotoxic MeG become mutagenic and 
carcinogenic (Karran 2001). 
The MMR-dependent cytotoxic response is elicited specifically in response to low dose 
exposure to alkylation damage (Stojic, Mojas et al. 2004). A defining feature of this response 
includes the induction of a G2 arrest, but only after cells have traversed through two S-phases 
(Stojic, Mojas et al. 2004, Mojas, Lopes et al. 2007, Mastrocola and Heinen 2010). Although MMR 
proteins recognize engineered MeG/T mismatches on DNA substrates in vitro, the molecular 
events following this recognition are unclear (Duckett, Drummond et al. 1996). All encompassing, 
two models have been proposed. The first model suggests that MMR directs excision on the newly 
synthesized daughter strand (Fig. 1-3). Hence, during resynthesis persistence of MeG on template 
DNA drives the recreation of the MeG/T mismatch (Kaina, Ziouta et al. 1997, Stojic, Mojas et al. 
2004, Mojas, Lopes et al. 2007). In this manner, MMR-directed MeG/T recognition initiates iterative 
cycles of futile repair. In support of this futile cycle model, introduction of an irreparable MeG base 
on the template DNA drives repeated MMR directed strand excision and gap filling across from 
MeG lesions (York and Modrich 2006). Correspondingly, loss of murine Exo1 or expression of an 
endonuclease dead PMS2 mutant in PMS2-/- cells confers resistance to alkylation damage, 
emphasizing the role of tract excision and processing in this MMR-directed DNA damage 
response (Erdeniz, Nguyen et al. 2007, Klapacz, Meira et al. 2009). Also, inability to faithfully 
repair and replicate these regions yields ssDNA gaps in both yeast and human cancer cells 
(Mojas, Lopes et al. 2007). Through mechanisms that are not well understood the ssDNA gaps 
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are tolerated, and cells continue progression into the next cell cycle. Forks encountering gapped 
template DNA collapse, leading to accumulation of double strand breaks (DSBs) (Stojic, Mojas et 
al. 2004, Mojas, Lopes et al. 2007). The collapsed forks and DSBs can be rescued by HR as 
evidenced by an increase in sister chromatid exchange (SCE) (Mojas, Lopes et al. 2007). 
Correspondingly, loss of HR further sensitizes MMR-proficient yeast and human cells to the 
cytotoxicity of MNNG, which is alleviated upon MMR loss. Inability to resolve all DSBs however 
triggers permanent G2 arrest through the activation of DNA damage sensing kinases and 
checkpoint proteins like Ataxia Telangiectasia and Rad3-related  (ATR), Ataxia Telangiectasia 
mutated (ATM), checkpoint kinase 1 (Chk1) and checkpoint kinase 2 (Chk2) (Stojic, Mojas et al. 
2004, Mojas, Lopes et al. 2007, Mastrocola and Heinen 2010). Therefore, in this model secondary 
damage accumulation, like ssDNA gaps and DSBs, resulting from MMR-directed futile repair is 
responsible for cytotoxicity of MeG lesions.   
An alternative model suggests that MMR proteins recognizing MeG/T mismatches are 
capable of directly activating DNA damage responses (Fig. 1-3). In this direct signaling model, 
MMR proteins along with other factors act as a platform for the recruitment and activation of DNA 
damage sensing kinases and checkpoint points (Yoshioka, Yoshioka et al. 2006, Li, Pearlman et 
al. 2016). In support of this, MSH2 was found to interact with ATR directly in vitro (Wang and Qin 
2003). ATR, Chk1 and Chk2 coimmunoprecipitate with MSH2-MSH6 complex in response to 
alkylation damage (Brown, Rathi et al. 2003, Adamson, Beardsley et al. 2005, Liu, Fang et al. 
2010). Similarly, MLH1-PMS2 complex interacts with ATR-activator, TOPBP1 (Topoisomerase II-
binding protein 1) and ATM (Brown, Rathi et al. 2003, Liu, Fang et al. 2010). Interestingly, other 
canonical factors important to ATR-Chk1 activation did not enrich on damaged chromatin or 
interact with MMR proteins (Liu, Fang et al. 2010) . Additionally, in vitro MMR proteins activate 
ATR-Chk1 kinases in response to MeG/T and not G/T mismatches containing DNA substrates  
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Fig 1-3. Processing and repair of cytotoxic MeG lesions created upon exposure to SN1 DNA 
alkylating agents. 
Alkylation of guanine residues by SN1 DNA alkylating agents creates a mutagenic MeG lesion 
within DNA. These lesions can be directly repaired by O6-methylguanine-DNA methyltransferase 
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(MGMT). But MeG lesions that escape this repair are preferentially mispaired with thymidine during 
DNA replication. IN the MMR-directed futile cycle model, MeG/T mismatch recognition by 
eukaryotic MMR homologue MutSα (MSH2-MSH6) initiates excision and resynthesis of error 
containing daughter strand. However, persistence of MeG on the template DNA leads to MMR-
directed futile cycles of repair. Inability to replicate across MeG lesions causes ssDNA gap 
accumulation without affecting cell cycle progressing. In the subsequent S phase however, 
replication forks collapse at these gapped substrates causing DSB accumulation. This activates 
ATR-Chk1 and ATM-Chk2 DNA damage signaling causing a G2 arrest. Although HR repair 
attempts repair of these DSBs at the expense of accumulating sister chromatid exchanges (SCE) 
and chromosomal aberrations, the overwhelming burden of cytotoxic DSBs leads to cell death. 
Therefore, in this model secondary damage accumulation, like ssDNA gaps and DSBs, resulting 
from MMR-directed futile repair is responsible for cytotoxicity of MeG lesions. Alternatively, the 
MMR directed recognition of MeG lesions has been suggested to initiate a direct signaling module 
wherein DNA damage sensing kinases and their co-activators, create a platform at MeG/T 
mismatches for the activation of ATR-Chk1 signaling and ATM-Chk2 signaling that can lead to 
activation of a G2 arrest and eventually cell death. (Adapted with permission from (Fu, Calvo et 
al. 2012)) 
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(Yoshioka, Yoshioka et al. 2006). But most strikingly, mouse embryonic fibroblasts expressing 
missense mutants of Msh2G674A and Msh6T1217D that abrogated mismatch correction still 
retained sensitivity to MNNG (Lin, Wang et al. 2004, Yang, Scherer et al. 2004).  Together, these 
finding suggested that by directly interacting with DNA damage sensing kinases and their co-
activators, MMR proteins act as a platform at MeG/T mismatches for the activation of ATR-Chk1 
and ATM-Chk2 signaling. However, this model fails to explain why MMR proteins that respond to 
MeG/T in the first S-phase, elicit a cell cycle arrest only in the second cell cycle after damage 
exposure. 
 
IV. HUMAN PLURIPOTENT STEM CELLS 
 
During development, embryonic stem cells (ESCs) divide rapidly and differentiate into all 
cell lineages of the organism. Thus, acquisition and propagation of genomic aberrations in hESCs 
could have deleterious consequences for development and tissue homeostasis, promoting 
disease and even death. Hence the need for maintenance of genomic stability is likely heightened 
in these cells (Rocha, Lerner et al. 2013). Furthermore, the ability to fine tune culture conditions 
to direct differentiation of human pluripotent stem cells (hPSCs) such as hESCs and induced 
pluripotent stem cells into specific cell types creates tremendous potential for their use in 
regenerative medicine, disease modeling, drug screening and testing. Yet a lack of a thorough 
understanding of how they deal with genotoxic stresses limits their potential in regenerative 
medicine. 
Initial studies have demonstrated certain recurring themes by which hPSCs deal with DNA 
damage. They have an increased propensity to undergo apoptosis when exposed to various 
genotoxic stresses (Adams, Golding et al. 2010, Barta, Vinarsky et al. 2010, Momcilovic, 
Knobloch et al. 2010, Wilson, Sun et al. 2010, Fan, Robert et al. 2011, Desmarais, Hoffmann et 
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al. 2012, Luo, Gopalakrishna-Pillai et al. 2012, Sokolov and Neumann 2012, Insinga, Cicalese et 
al. 2013, Liu, Guan et al. 2013, Rocha, Lerner et al. 2013, Suvorova, Kozhukharova et al. 2013). 
The tumor suppressor p53 is a crucial effector of the apoptotic response in hPSC (Qin, Yu et al. 
2007, Dumitru, Gama et al. 2012, Liu, Guan et al. 2013). Exposure to genotoxic stress causes 
stabilization and activation of a p53 dependent apoptotic response. In somatic cells, stress-
induced p53 engage in transcription dependent and independent modes of apoptotic induction 
(Villunger, Michalak et al. 2003, Green and Kroemer 2009). In hPSCs however, p53’s role as a 
trans-activator of pro-apoptotic genes is dispensable for apoptotic induction. Reduction in p53 
expression but not inhibition of p53-nuclear translocation attenuates apoptotic induction in 
damaged hPSCs (Grandela, Pera et al. 2007, Qin, Yu et al. 2007). Conversely, translocation of 
p53 to the mitochondria is essential for activating the apoptotic response (Grandela, Pera et al. 
2007, Qin, Yu et al. 2007, Liu, Guan et al. 2013). By interacting with anti-apoptotic factors Bcl-xl 
and Bcl-2, p53 induces mitochondrial outer membrane permeabilization (MOMP) and apoptosis 
(Chipuk, Kuwana et al. 2004, Leu, Dumont et al. 2004). Although these mechanisms are 
synonymous with those found in somatic cells, induction of a p53-dependent apoptosis in 
damaged hESCs is accelerated as compared to their differentiated counterparts. Interestingly, 
two mechanisms have been identified to prime hESCs for rapid apoptotic induction. In the first 
mechanism, hESCs maintain pre-activated proapoptotic protein Bax protein within the Golgi, 
which upon damage exposure undergoes rapid p53 dependent translocation to the mitochondria 
to initiate MOMP (Dumitru, Gama et al. 2012). Alternatively, hESCs can exhibit high mitochondrial 
priming, wherein they express higher levels of proapoptotic protein PUMA but lower levels of 
antiapoptotic protein Bcl-2 compared to their differentiated counterparts. This lowers the apoptotic 
threshold required to elicit a damage induced p53 mitochondrial program (Liu, Guan et al. 2013). 
Furthermore, both these hESC apoptotic priming mechanisms are rapidly lost in response to 
differentiation.  
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In addition to favoring elimination of damaged cells, hESCs express higher levels of DNA 
repair factors and repair various DNA lesions more efficiently compared to somatic cells 
(Maynard, Swistowska et al. 2008, Momcilovic, Knobloch et al. 2010). hESCs favor high fidelity 
homologous recombination (HR) repair rather than error prone non-homologous end joining 
(NHEJ) repair of DSBs (Adams, Golding et al. 2010, Nagaria, Robert et al. 2013). Inhibition of 
DSB damage sensing kinases, ATM and DNA dependent protein kinase (DNA-PKcs), increases 
sensitivity of hESCs to the topoisomerase I inhibitor, camptothecin (Garcia, Videla Richardson et 
al. 2014). Interestingly, hESCs do not activate G1/S checkpoint in response to irradiation damage. 
Instead exposure to gamma irradiation induced rapid cell death and is accompanied by activation 
of ATM and its downstream targets Chk2 and p53 (Momcilovic, Choi et al. 2009). DSBs undergo 
Rad51-mediated HHR resulting in sister chromatid exchanges (SCE) and cells elicit a temporary 
G2 arrest, before resuming cell cycle progression (Momcilovic, Knobloch et al. 2010). Conversely, 
ultra-violet radiation-C range (UVC) light exposure triggers Chk1/Chk2-mediated degradation of 
CDC25A (cell division cycle 25 homolog A), prevents cyclin dependent kinase 2 (CDK2) activation 
and induction of a G1 arrest (Barta, Vinarsky et al. 2010). In sharp contrast to the presence of 
some observable checkpoint activation in response to other genotoxic stresses, hESCs treated 
with agents that block the replication fork progression fail to activate the Chk1 mediated intra S-
phase checkpoint. Instead, hESCs undergo rapid apoptosis upon exposure to replication stress 
inducers like excess thymidine, which disrupts nucleotide pools, or cisplatin which creates inter- 
and intra-strand DNA crosslinks (Desmarais, Hoffmann et al. 2012). 
 
V. REPLICATION STRESS RESPONSE 
 
Replicative DNA polymerases frequently encounter obstacles that block fork progression 
as they undertake the daunting task of accurately replicating a 6 billion base pair genome. These 
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hindrances to fork progression can result from DNA damage exposure, DNA crosslinks, 
secondary DNA structure formation, insufficient nucleotide pools and run-ins with the transcription 
machinery (Zeman and Cimprich 2014). Encountering these lesions on the lagging strand might 
not have lasting consequences for fork progression due to the continual synthesis and priming of 
new Okazaki fragments. Conversely, fork stalling on the leading strand can slow fork progression 
and in extreme cases lead to uncoupling of the helicase from DNA polymerase (Cortez 2015). 
The resulting ssDNA-dsDNA junctions at stressed forks serve as a hub for the recruitment and 
interaction of multiple factors essential to the activation of an ATR-Chk1 replication stress 
response.  
 Replication stress signaling is initiated by the binding of ssDNA binding protein, RPA, to 
ssDNA formed at stalled forks (Fig. 1-4). ATR in association with its obligate partner ATRIP is 
recruited to sites of RPA-coated ssDNA (Cortez, Guntuku et al. 2001, Zou and Elledge 2003). 
Independently, clamp loader Rad17 loads PCNA- like heterotrimeric ring complex Rad9-Rad1-
Hus1 (9-1-1 complex) at ssDNA-dsDNA junctions at stalled forks (Bermudez, Lindsey-Boltz et al. 
2003, Majka, Binz et al. 2006). ATR-activator TopBP1 is recruited to these sites though an 
interaction with a constitutively phosphorylated site on Rad9 (Ser387) that is essential for TopBP1 
binding (Delacroix, Wagner et al. 2007). TopBP1 contains an essential and conserved ATR-
activation domain (AAD) and overexpression of this domain alone can induce ATR activation in 
absence of DNA damage (Kumagai, Lee et al. 2006, Mordes, Glick et al. 2008). Once activated, 
ATR then phosphorylates downstream targets Rad17 (Ser 635) and RPA (Ser 33) (Bao, Tibbetts 
et al. 2001, Vassin, Anantha et al. 2009). These phosphorylation sites create docking sites for 
Claspin that mediates ATR dependent Chk1 activation (Wang, Zou et al. 2006). Together ATR 
and Chk1 kinases can phosphorylate various target proteins to orchestrate a response that 
includes regulation of origin firing, stabilization of stalled replication forks, induction of cell cycle 
arrest to prevent entry into mitosis and facilitating fork restart after removal of the fork stalling  
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Fig 1-4. Activation of ATR-Chk1 signaling at stalled replication forks.  
ATR in association with ATRIP are recruited to sites of RPA coated single stranded DNA stretches 
formed at stalled replication forks. Rad17 loaded PCNA- like heterotrimeric ring complex Rad9-
Rad1-Hus1 (9-1-1 complex) at 5’ primer junctions can interact ATR-activator, TOPBP1. Activated 
ATR activates the downstream checkpoint kinase Chk1 in a Claspin dependent manner. 
Together, ATR and Chk1 kinase phosphorylate target proteins to induce a replication stress 
response that includes but is not restricted to delaying and coordinating origin firing, induction of 
cell cycle arrest, and stabilization of stalled fork structures (Adapted with permission from 
(Cimprich and Cortez 2008)). 
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agent or lesion (Zeman and Cimprich 2014). Herein, the mechanisms of some of these signaling 
responses are highlighted. 
 
Cell cycle arrest 
The ATR-Chk1 signaling also orchestrates a G2/M cell cycle arrest following DNA 
damage. The ATR activating ssDNA-dsDNA junctions/structures can result from DSB resection 
or those formed at stalled forks due to polymerase and helicase uncoupling. ATR-activated Chk1 
kinase can directly phosphorylate the protein phosphatase, CDC25A and target it for degradation. 
This prevents cdc25A from removing inhibitory phosphorylations on CDK1/2 of the cyclin-cdk 
complex, preventing cell cycle progression and induction of cell cycle arrest.  
 
Regulation of origin firing 
 In eukaryotes, DNA replication is initiated at multiple sites called origins of replication to 
ensure efficient and timely completion of DNA replication in S phase. In every cell cycle, origins 
must be licensed during late mitosis and G1 (Blow, Ge et al. 2011). This ATP-dependent process 
involves the assembly of a pre-replicative complex which consists of the origin recognition 
complex (ORC), CDC6 (cell division cycle 6), CDT1 (chromatin licensing and DNA replication 
factor 1) and two molecules of the heterohexameric replicative helicase MCM2-7 
(minichromosome maintenance complex) (Gillespie, Li et al. 2001, Remus, Beuron et al. 2009, 
Gambus, Khoudoli et al. 2011). The ORC-CDC6 complex recognizes origin DNA and recruits 
CDT1. MCM2-7 then interacts with CDT1 at origins and loads onto DNA (Tsuyama, Tada et al. 
2005). S-phase CDKs (cyclin-dependent kinase) also restrict origin licensing to G1 by preventing 
further loading of MCM2-7 complexes. The firing of replication origins is initiated in S-phase by 
the phosphorylation of pre-ORCs by two S-phase kinases, DBF4 dependent Cdc7 kinase (DDK) 
and cyclin-dependent kinase (CDK) (Kang, Warner et al. 2014, Fragkos, Ganier et al. 2015). 
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CDC45 (cell division cycle 45) and the GINS complex can then associate with and activate the 
MCM2-7 helicase (Ilves, Petojevic et al. 2010, Blow, Ge et al. 2011). DNA-unwinds at these fired 
origins and DNA replication is initiated. 
 DNA replication is initiated at origins distributed all over the genome to ensure the timely 
completion of our extensive genome. DNA replication is spatiotemporally regulated wherein 
origins within specific regions fire during specific stages of S-phase. This spatiotemporal 
regulation can be visualized as the onset of distinct DNA replication patterns that correspond to 
how far along cells are within S phase (Fig. 1-5) (Chakalova, Debrand et al. 2005). ATR and Chk1 
are key regulators of origin firing both in an unperturbed and perturbed S phase (Cortez 2015, 
Saldivar, Cortez et al. 2017). They inhibit excess or unscheduled origin firing and coordinate origin 
firing under conditions that induce fork stalling. This ensures the efficient distribution and supply 
of nucleotides and replication factors needed during DNA replication. Accordingly, deregulated 
origin firing in the absence of Chk1 kinase activity decreases inter-origin distance even in the 
absence of replication stress. This is accompanied by the premature activation of late S-phase 
origin in early S phase, increased damage and replication stress accumulation and decreased 
cell survival (Maya-Mendoza, Petermann et al. 2007, Cortez 2015, Saldivar, Cortez et al. 2017). 
These effects are alleviated upon knockdown of replication initiation factor CDC45 suggesting 
that increased origin firing in the absence of Chk1 regulation causes accumulation of lethal double 
strand breaks (Rodriguez, Gagou et al. 2008, Gagou, Zuazua-Villar et al. 2010). Concurrently, 
replication stress induced ATR and Chk1 activation prevents global origin firing by blocking 
CDC45 loading.   
 Interestingly, the number of origins licensed for replication is 3 to 20-fold higher than that 
required for completion of DNA replication in an unperturbed S phase (Alver, Chadha et al. 2014). 
In the absence of fork stalling, reduction in origin licensing by knockdown of proteins of the MCM2-
7 complex does not affect DNA replication rates. However, when fork stalling occurs, otherwise  
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Fig 1-5. Spatiotemporal regulation of DNA replication. 
Incorporation of nucleoside analogue upon pulse labelling marks active origin clusters. Images 
show DNA replication patterns typically observed with progression through S phase a. In early S 
phase, active replication foci distributed throughout the nucleus replicate euchromatin. b. In mid 
S phase, DNA around the nuclear periphery and nucleolar regions is replicated. c. In late S phase, 
large foci of active DNA replication clusters correspond to replication of facultative and constitutive 
heterochromatin.  (Reproduced with permission from (Chakalova, Debrand et al. 2005)) 
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dormant origins close to stalled forks can fire to compensate for stalled forks, ensuring completion 
of DNA replication. Therefore, while reduction in MCM2-7 levels have no effect on normal 
replication rates, these cells exhibit delayed S phase progression and decreased cell survival 
when exposed to replication stress inducers (Woodward, Gohler et al. 2006, Blow, Ge et al. 2011). 
ATR is crucial to coordinating the completion of DNA replication from these otherwise dormant 
origins under conditions of replication stress. Although the exact mechanism of this remains 
elusive, ATR exerts a paradoxical coordination of origin firing. Upon exposure to replication stress, 
ATR prevents activation of DNA replication within inactive or late-S phase firing origins achieving 
a global effect in suppressing origin firing. Paradoxically, ATR-Chk1 promotes firing of dormant 
origins adjacent to stalled replication forks within active DNA replication clusters (Ge and Blow 
2010). This inhibition of global origin firing prevents the accumulation of stalled forks while 
facilitating redirection of crucial replication factors to stalled forks within actively replicating regions 
to enable completion of DNA replication from dormant origins (Fig. 1-6). These mechanisms 
function together to protect fork integrity.  
 Consequentially, inhibition of ATR signaling causes unscheduled and deregulated origin 
firing. The effects of replication stress are exacerbated under these circumstances, leading to the 
titration out of DNA replication factors that are crucial for replication and fork protection resulting 
in extensive DNA damage accumulation and loss of viability. Furthermore, even under conditions 
of unscheduled origin firing, fork protection mechanisms fail much after the inhibition of ATR 
signaling (Toledo, Altmeyer et al. 2013). This has recently been attributed to the titration out of 
ssDNA binding protein RPA that is essential for protecting stalled forks. Although RPA pools are 
sufficient to protect ssDNA resulting from fork stalling, the increase in ssDNA that accompanies 
unscheduled origin firing amid replication stress, leads to a rapid exhaustion of available RPA 
pools. Indeed, increasing or decreasing RPA pools correlates with the extent of protection offered 
to accumulating ssDNA regions, decelerating or accelerating the impending fork collapse that  
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Fig 1-6. Regulation of origin firing by ATR-Chk1 replication stress response.  
(A) During unperturbed S phase (left), a few origins fire within DNA replication clusters activated 
in early S phase. With progression through S phase, origins of replication are activated within late 
S-phase DNA replication clusters. However, in the presence of replication stress (right) replication 
forks within the DNA replication clusters active in early S-phase stall. Dormant origins in the 
vicinity of stalled forks are activated to promote completion of DNA-replication in early S phase 
replication clusters. Concurrently, the ATR-Chk1 replication stress checkpoint inhibits origin firing 
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within inactive/late S phase replication clusters. (B) In the presence of replication stress firing of 
dormant origins rescue DNA replication between stalled forks. In the absence of dormant origin 
firing replication cannot be completed between stalled forks, which results in DNA damage 
accumulation and induction of apoptosis. (Reproduced with permission from (Ge and Blow 2010)) 
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 accompanies unscheduled origin firing amid replication stress respectively. Also, these effects 
are alleviated upon inhibition of origin firing. These results suggest that replication stress induced  
ATR directed control on origin firing is crucial yet indirect mechanism for preventing fork collapse 
(Toledo, Altmeyer et al. 2013, Cortez 2015, Saldivar, Cortez et al. 2017). 
 
Regulation of fork remodeling 
 Upon encountering lesions that stall replication forks, forks can regress or reverse giving 
rise to what are commonly referred to as chicken foot structures. The formation of these structures 
reinstates ssDNA regions that form at stalled forks into dsDNA limiting ssDNA accumulation 
(Cortez 2015). These structures are also permissive to template switching facilitating replication 
of DNA that was otherwise impermissible due to the presence of the fork stalling lesions (Cortez 
2015, Saldivar, Cortez et al. 2017). Although these mechanisms can permit fork protection, ATR 
ensures tight regulation of the enzymes involved (Couch, Bansbach et al. 2013). The DNA 
translocase, SMARCAL1, is one such downstream target of ATR. Upon RPA-dependent 
recruitment to stalled forks, SMARCAL1 catalyzes fork regression (Yusufzai and Kadonaga 2008, 
Bansbach, Betous et al. 2009, Ciccia, Bredemeyer et al. 2009). ATR-dependent phosphorylation 
of SMARCAL1 at Ser 625 is essential to regulating its fork remodeling activity. However, 
deregulated fork processing by SMARCAL1 in the absence of ATR activity leads to aberrant fork 
structures that are substrates of SLX4-dependent structure nucleases (Couch, Bansbach et al. 
2013). This leads to rapid fork collapse, DNA damage accumulation and loss of viability. 
Furthermore, these effects are alleviated upon the overexpression of SMARCAL1 S625D, a 
phosphomimetic mutant of ATR regulation (Fig. 1-7). This work emphases the importance of ATR 
regulation in remodeling and stabilization of stalled forks.   
Additionally, the regulated origin firing, and fork remodeling mechanisms might function 
concurrently to prevent replication fork collapse. In the absence of ATR regulation, continued  
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Fig 1-7. The replication stress checkpoint regulates fork regression and remodeling. 
The DNA translocase SMARCAL1 catalyzes the regression of stalled replication forks resulting in 
the formation of a chicken foot structure. In checkpoint proficient cells, ATR regulates fork reversal 
and is essential for maintenance of fork integrity. In checkpoint-deficient cells however, stalled 
forks undergo uncontrolled remodeling. This results in the formation of structures that are 
susceptible to cleavage by SLX4-dependent structure nucleases and fork collapse. (Reproduced 
with permission from (Cortez 2015)). 
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origin firing would yield increased number of stalled forks that undergo deregulated remodeling, 
increasing their susceptibility to endonucleases and causing widespread fork collapse. 
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CHAPTER 2 
 
COMING INTO FOCUS: DISCOVERY OF A NOVEL MMR-DEPENDENT DAMAGE 
RESPONSE IN HUMAN PLURIPOTENT STEM CELLS 
(D.G. is responsible for data shown in Fig. 2- 4B, 4C, 5, 6, 7, 8 and 9B) 
 
Genomic integrity dictates vitality and normal physiological function. Accumulation of 
mutations and genomic aberrations could have deleterious consequences for development, 
tissue homeostasis, disease progression such as tumorigenesis and even death. As noted earlier 
a functional MMR pathway is crucial for genomic stability. MMR directed mismatch removal 
increases replication fidelity by three orders of magnitude (Kunkel and Erie 2005). Consequently, 
loss of functional MMR leads to an increase in mutation rate which promotes tumorigenesis. The 
inheritance of mutations in MMR genes causes a colorectal cancer predisposition syndrome, 
Lynch syndrome. Also, MMR function is lost in 10-40% of spontaneously arising colorectal and 
other cancers (Lynch, Snyder et al. 2015).  
 
I. MMR-DEPENDENT DNA DAMAGE RESPONSE: LESSONS LEARNED FROM STUDIES IN-VITRO AND 
CANCER CELL MODELS 
The MMR pathway is essential for invoking a cell cycle arrest and apoptotic response to 
certain DNA damaging agents (Duckett, Drummond et al. 1996, Li, Pearlman et al. 2016). Loss 
of MMR confers a 100-fold decease in sensitivity to chemotherapeutic SN1 DNA alkylating agents 
(Karran 2001). In this regard, understanding the MMR mechanism could guide strategies for the 
prevention and treatment of cancer. As outlined earlier, this MMR-dependent sensitivity to these 
drugs stems from the generation of mutagenic MeG lesions that preferentially mispair with 
thymidine during DNA replication (Murray 1987, Kaina, Ziouta et al. 1997). The events following 
the recognition of these MeG/T mismatches however have remained largely controversial (Duckett, 
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Drummond et al. 1996). Results from test-tube based biochemistry experiments and responses 
of transformed cells to MeG/T lesion formation have failed to address if and how MMR directed 
repair is executed at eukaryotic cellular replication forks. This is further complicated by the 
temporal disconnect between the MMR-dependent recognition of MeG/T mismatches that occurs 
in the first S-phase after exposure to SN1 type alkylating agents, and the requirement that cells 
must traverse through two S phases to invoke a permanent G2 arrest and eventual cell death 
(Stojic, Mojas et al. 2004, Mastrocola and Heinen 2010). Yet, two independent, but not mutually 
exclusive models have emerged from these studies (Fig. 2-1).   
A futile cycle model suggests the MMR directs excision of daughter strand DNA across 
from the MeG lesion (Kaina, Ziouta et al. 1997, Stojic, Mojas et al. 2004, Mojas, Lopes et al. 2007, 
Noonan, Shah et al. 2012). Persistence of MeG on the template strand redirects MeG/T mismatch 
resynthesis, initiating iterative cycles of MMR directed repair. Unable to faithfully replicate across 
MeG lesions, cells accumulate ssDNA gaps after the first cell cycle (Mojas, Lopes et al. 2007). In 
the subsequent S phase, replication forks collapse at these gaps creating DSBs and the induction 
of a permanent G2 arrest (Stojic, Mojas et al. 2004, Mojas, Lopes et al. 2007). A second, direct 
signaling model, suggests that, upon MeG/T recognition MMR proteins forms a docking site for 
recruitment and activation of proteins important for signaling a cell cycle arrest (Li, Pearlman et 
al. 2016). Particularly, MMR proteins are proposed to form a direct interaction platform for ATR 
and it’s activator TOPBP1 bypassing the need for the assembly of an ATR-activation module that 
forms at ssDNA-dsDNA junctions, a prerequisite for canonical ATR-Chk1 activation (Liu, Fang et 
al. 2010). This model however falls short on explaining the temporal disconnect between the 
MMR-dependent activation of these cell cycle regulators in the first S phase and onset of a G2 
arrest in the subsequent cell cycle.  
As evidenced by these models, mechanistic details of the MMR-directed activity following 
MeG/T lesion recognition remain poorly understood. It is unclear if and how MMR- dependent  
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Fig 2-1. Futile cycle and direct signaling models for MMR-dependent cytotoxic response 
to MeG lesion formation.  
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recognition of MeG/T lesions affects cellular replication forks. In-vitro studies fail to recapitulate the 
complexities of how MMR activity might coordinate with the replication machinery. In turn 
evidence in support of the futile cycle model indicate that repair activity does not impact on fork 
progression or result in fork reversal, a structure commonly formed at and likely important for 
protection of stalled forks (Mojas, Lopes et al. 2007). In addition, the direct signaling model poses 
that MeG/T bound MMR can directly activate cell cycle checkpoint proteins (Li, Pearlman et al. 
2016). Considering this, MMR directed futile repair and/or signaling has been speculated to be 
executed behind and uncoupled from the ongoing replication fork machinery.  
 
II. IDENTIFICATION OF A NOVEL MMR-DEPENDENT DNA DAMAGE RESPONSE IN HUMAN PLURIPOTENT 
STEM CELLS 
Transformed cells continually accumulate genetic mutations in culture. Furthermore, to 
protect cells against stresses associated with oncogenic transformation, these cells may have an 
increased dependence, activation or expression of various of DNA damage response genes. 
Specifically, as discussed before, ATR-Chk1 signaling is crucial for protection of forks and cells 
experiencing replication stress. In fact, an increase in replication stress is thought to accompany 
oncogenic transformation (Zeman and Cimprich 2014). These cells therefore have increased 
dependence on ATR-Chk1 signaling for survival. Indeed, inhibition of ATR activity in cells 
experiencing oncogene induced replication stress results in rapid DNA damage accumulation and 
loss of cell viability (Ruzankina, Schoppy et al. 2009, Gilad, Nabet et al. 2010, Murga, Campaner 
et al. 2011, Lopez-Contreras, Gutierrez-Martinez et al. 2012, Schoppy, Ragland et al. 2012). 
Given these altered DNA damage responses, the MMR-dependent DNA damage response 
observed in transformed cell models could have arisen from carrier mutations and/or altered DNA 
damage responses that accompany transformation. We therefore sought to understand the MMR-
dependent DNA damage response in a non-transformed cell model, human pluripotent stem cells 
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(hPSCs). Furthermore, we could harness the pluripotency of this system and differentiate these 
cells into human intestinal and colonic organoids. Since loss of MMR promotes tumorigenesis in 
the colon it provides for an opportunity to develop a model system to understand how MMR loss 
could promote tumorigenesis. 
To characterize the MMR-dependent DNA damage response in hPSCs, cell cycle profiles 
of human embryonic stem cell line (CT-2), human induced pluripotent line (YK26) and it’s parental 
human dermal fibroblasts (HDFa) treated with MNNG for 48 h were examined. Two cancer lines, 
HeLa (MMR proficient) and Hec59 (MMR deficient), were similarly treated as positive and 
negative controls of the MMR-dependent DNA damage response, respectively. As expected, 
MNNG treatment caused increased accumulation of MMR proficient Hela cells in G2/M phase, an 
effect which was completely abrogated in MMR deficient Hec59 cells (Fig. 2-2A). These results 
were consistent with our previous work, indicating that MNNG treatment induces a MMR-
dependent G2/M arrest in cancer cell models. Interestingly, cell cycle profiles of both hPSCs lines, 
YK26 and CT-2, exposed to alkylation damage displayed large sub-G1 peaks, indicative of 
apoptotic induction (Fig. 2-2A). Furthermore, the knockdown of levels of MMR proteins, MSH2 
and MLH1, in YK26 iPSCs alleviated sensitivity to alkylation damage as seen by the absence of 
this sub-G1 peak upon MNNG treatment (Fig. 2-2B, 2C). These results suggested that hPSCs 
elicit MMR-dependent hypersensitivity to MNNG (Lin, Gupta et al. 2014).  
iPSCs have a characteristic 16 h cell cycle owing to a shortened G1 phase as opposed to 
the 24 h cell cycle duration of most cancer cell lines (Becker, Ghule et al. 2006). Therefore, cells 
could have traversed through two S-phases during the 48 h of MNNG exposure before inducing 
apoptosis. To assess the timing of this apoptotic response nocodazole synchronized YK26 cells 
were treated with MNNG in G1 phase and their cell cycle progression was monitored. Cell cycle 
profiles indicated that mock treated cells are predominantly in the first S phase 8 h post 
nocodazole release (Fig. 2-3). Exposure to alkylation damage however resulted in a large fraction 
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of cells with sub-G1 DNA content at this early time point. Furthermore, knockdown of MMR 
proteins completely abrogated this response to alkylation damage (Fig. 2-3). Strikingly, these 
results indicated that MMR-dependent hypersensitivity to alkylation damage involves the 
induction of an apoptotic response within the first S-phase of damage exposure (Lin, Gupta et al. 
2014).  
 
EXPOSURE TO ALKYLATION DAMAGE DOES NOT INDUCE ACTIVATION OF DNA DAMAGE CHECKPOINT 
KINASES IN HUMAN PLURIPOTENT STEM CELLS  
 The novel MMR-dependent damage response of hPCSs contradicted the well-established 
and delayed G2 arrest observed in cancer cells in the second cell cycle after damage exposure. 
It suggested that MMR-dependent recognition of MeG/T mismatches in the first S-phase leads to 
apoptotic induction in hPSCs. These results supported a direct signaling model, wherein MMR-
directed MeG/T lesion recognition activates DNA damage signaling kinases and checkpoint 
proteins initiating early apoptotic induction (Li, Pearlman et al. 2016). To test this, iPSCs and the 
HeLa cancer cell line were examined for activation of DNA damage checkpoint kinases, Chk1 
and Chk2, 24 h after exposure to MNNG for 24 h. Activation of Chk1 and Chk2 was assessed 
by induction of their phosphorylation at Ser-345 and Thr-68 respectively (Stojic, Mojas et al. 
2004, Mastrocola and Heinen 2010, Noonan, Shah et al. 2012). Surprisingly, although damage 
exposure induced phosphorylation and activation of Chk1 and Chk2 in HeLa cells, no such 
activation was observed in damaged iPSCs (Fig. 2-4A). Consistently, two other hESC lines, H1 
and CT-2, showed no observable Chk1 or Chk2 activation following damage exposure (Fig. 2-
4B). However, dephosphorylation of these sites late in apoptosis could account for the lack of 
observable Chk1 and Chk2 activation at later time points. Therefore, Chk1 and Chk2 activation 
was assessed at various time points soon after exposure of nocodazole-synchronized hPSCs 
to alkylation damage. Even at these early time points, no induction of Chk1 or Chk2  
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Fig 2-2. Alkylation damage induces a MMR-dependent apoptotic response in hPSC  
(A) Representative cell cycle profiles of HeLa, Hec59, CT-2, YK26 and HDFa cells lines treated 
with 2 μM MNNG for 48 h. Arrows point to cells with sub-G1 DNA content indicative of apoptosis. 
(B) Immunoblot of mismatch repair proteins MSH2, MSH6, MLH1 and PMS2 confirming 
knockdown of MSH2 and MLH1 in YK26 iPSCs. (C) Representative cell cycle profiles of control, 
MSH2 knockdown (MSH2 KD) and MLH1 knockdown (MLH1 KD) YK26 cells treated with 2 μM 
MNNG for 48 h. Adapted from (Lin, Gupta et al. 2014) 
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Fig 2-3. Alkylation damage induces a MMR-dependent apoptotic response in hPSC directly 
out of the first S-phase  
Representative cell cycle profiles of control, MSH2 knockdown (KD), or MLH1 knockdown YK26 
cells harvested at indicated times after release from mitotic synchronization and exposed to 2 μM 
MNNG in G1. Arrows point to cells with sub-G1 DNA content indicative of apoptosis. Adapted from 
(Lin, Gupta et al. 2014) 
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phosphorylation was observed in damaged iPSCs as compared their mock treated iPSCs (Fig. 2-
4C). However, γH2AX, a marker of replication stress and DSBs, was strongly induced at time 
points corresponding to early apoptotic induction (Fig. 2-4C). These results indicated that MMR-
dependent recognition of MeG/T mismatches in the first S-phase leads to apoptotic induction 
without the activation of checkpoint kinases (Lin, Gupta et al. 2014).  
 
DNA DAMAGE SENSING KINASES INDUCE MMR-DEPENDENT P53 STABILIZATION AND ACTIVATION IN 
HUMAN PLURIPOTENT STEM CELLS EXPOSED TO ALKYLATION DAMAGE 
 We assessed the role of the tumor suppressor protein, p53, in apoptotic induction in 
damaged iPSCs. Although p53 undergoes rapid turnover, its phosphorylation by DNA-damage 
sensing kinases like ATR and ATM in response to various genotoxic stresses leads to p53 
stabilization in hPSCs (Banin, Moyal et al. 1998, Tibbetts, Brumbaugh et al. 1999, Grandela, 
Pera et al. 2007). Subsequently, p53 activates a transcriptional and/or mitochondrial apoptotic 
program (Liu, Guan et al. 2013). We therefore, examined stabilization and phosphorylation of 
p53 at Ser15 in iPSCs in response to alkylation damage. As expected, alkylation damage 
induced rapid p53 phosphorylation and stabilization in iPSCs which was greatly reduced upon 
MSH2 knockdown (Fig. 2-5A). We next examined which DNA-damage sensing kinases 
activated p53 in damaged hPSCs. To this end, activation of ATR and ATM was assessed in 
YK26, H1 and Hela cells 24 h after damage exposure. MNNG treatment induced activation of 
both ATR and ATM in all three cell lines, as seen by phosphorylation of Ser 1981 and Ser 428, 
respectively (Fig. 2-5B, 5C) (Bakkenist and Kastan 2003, Liu, Shiotani et al. 2011). Furthermore, 
addition of small molecule inhibitors to ATR and ATM kinase activities resulted in a partial 
reduction in levels of p53 phosphorylation and stabilization in response to alkylation damage 
(Fig. 2-5D, 5E). These results suggested that ATR and ATM damage sensing kinases are 
activated upon exposure to alkylation damage. Together they activate p53 in a MMR-dependent 
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Fig. 2-4. Alkylation damage induces DNA damage marker γH2AX in hPSCs but not the 
activation of checkpoint kinases, Chk1 and Chk2. 
(A) Immunoblot of P-Chk1 (Ser 345), Chk1, P-Chk2 (Thr 48), Chk2 in YK26 and HeLa cells 
harvested 24 h after treatment with 2 μM MNNG for 24 h. Actin used as a loading control. (B) 
Immunoblot of P-Chk1 (Ser 345), Chk1, P-Chk2 (Thr 48), Chk2 in H1 and CT-2 hESCs harvested 
24 h after treatment with 2 μM MNNG for 24 h. Actin used as a loading control. (C) Nocodazole 
released YK26 treated with MNNG were harvest at indicated time points for western blot analysis. 
Immunoblot of P-Chk1 (Ser 345), Chk1, P-Chk2 (Thr 48), Chk2 and γH2AX with Actin used as a 
loading control. Adapted from (Lin, Gupta et al. 2014) 
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Fig. 2-5. ATR and ATM kinases can induce MMR-dependent p53 stabilization and activation 
in human pluripotent stem cells exposed to alkylation damage. 
(A) Immunoblot of P-p53 (Ser 15) and p53 in control and MSH2 knockdown (MSH2 KD) YK26 
cells after treatment with 2 μM MNNG for 24 h. Actin used as a loading control. (B) Immunoblot 
of P-ATR (Ser 1981), ATR, P-ATM (Thr 428), ATM in YK26, H1 and HeLa cells after treatment 
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with 2 μM MNNG for 24 h. Actin used as a loading control (Experiment performed by Dipika 
Gupta). (C) Quantitation of western blots to determine mean fold-change in activation of ATR and 
ATM in YK26 cells upon MNNG treatment Western blots were. (D) Immunoblot of P-p53 (Ser 15) 
and p53 in H1 cells treated with 2 μM MNNG, an ATR kinase inhibitor (VE-821) and an ATM 
kinase inhibitor (KU5593) for 24 h. (E) Quantitation of western blots to determine mean fold-
change in activation and stabilization of p53 upon MNNG treatment in the presence and absence 
of inhibitors to ATR and ATM kinase activities. Adapted from (Lin, Gupta et al. 2014). 
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manner which likely drives apoptotic induction in damaged hPSCs (Lin, Gupta et al. 2014). 
 
I. PREMISE: WHY THE MMR-DEPENDENT DNA DAMAGE RESPONSE IN HUMAN PLURIPOTENT STEM 
CELLS INDUCES APOPTOSIS IN THE FIRST-S PHASE AFTER DAMAGE EXPOSURE?  
Our work in hPSCs identified a novel MMR-dependent DNA damage response. Although 
hPSCs have adapted their DNA damage responses to eliminate cells exposed to genomic insults, 
the hyper accelerated MMR-dependent DNA damage response was unforeseen. This apoptotic 
induction in the first S-phase sharply contrasted with the delayed G2 arrest previously 
characterized in cancer cells (Stojic, Mojas et al. 2004, Mastrocola and Heinen 2010, Lin, Gupta 
et al. 2014). While these results befitted the direct signaling model, we found that MMR does not 
activate checkpoint kinases in hPSCs exposed to alkylation damage exposure. Instead DNA 
damage sensing kinases, ATR and ATM, activate and stabilize p53 promoting apoptotic induction. 
Herein, the direct signaling model fails to reconcile the lack of checkpoint kinase activation and 
accelerated cell death observed in damaged hPSCs. We however cannot rule out that MMR 
undertakes a novel direct signaling module, leading only to p53 activation and apoptosis. This 
novel direct signaling response however fails to explain the rapid accumulation of DNA damage, 
as seen by the induction of γH2AX, in MNNG treated hPSCs. Paradoxically, the accumulation of 
secondary DNA damage as byproduct of MMR-directed repair reactions at MeG/T mispairs 
seemed more plausible. Yet, if these repair reactions proceeded independently and behind 
ongoing forks as predicted by earlier studies, it remained unclear why it would result in differential 
outcomes in two different model systems. Therefore, in this work we examined the effects of MMR 
dependent MeG/T lesion recognition on the first S-phase more carefully.  
Interestingly, a recent study concluded that hPSCs are extremely sensitive to 
perturbations to replication fork progression. hPSCs when treated with increased thymidine, which 
disrupts nucleotide pools, or cisplatin which creates inter- and intra-strand DNA crosslinks that 
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block the replication fork, fail to activate ATR-Chk1 signaling (Desmarais, Hoffmann et al. 2012). 
This signaling in transformed cells is crucial for protection of stalled replication forks, coordination 
of DNA replication completion and mitigation of DNA damage accumulation (Couch, Bansbach et 
al. 2013, Toledo, Altmeyer et al. 2013, Zeman and Cimprich 2014). Increased replication stress 
accompanies oncogene-induced transformation and these cells concurrently rely on upregulated 
DNA replication stress responses for survival. Failure to activate ATR-Chk1 under these 
conditions has been shown to cause accumulation of DSBs due to fork collapse and cell death 
(Ruzankina, Schoppy et al. 2009, Gilad, Nabet et al. 2010, Murga, Campaner et al. 2011, Lopez-
Contreras, Gutierrez-Martinez et al. 2012, Schoppy, Ragland et al. 2012, Couch, Bansbach et al. 
2013, Toledo, Altmeyer et al. 2013). 
 We therefore hypothesized that MMR must coordinate with DNA replication forks to 
correct MeG/T mispairs. However, as MeG lesions cannot be faithfully replicated, MMR-directed 
futile repair would disrupt progression of forks encountering these lesions. Furthermore, we 
predicted that the activation of Chk1 signaling in transformed cells mitigates the ensuing 
replication stress, facilitating the completion of replication and entry into the second cell cycle. In 
contrast, in hESCs the absence of this Chk1 signaling accelerates both DNA damage 
accumulation and sensitivity to alkylation damage.  
To establish the efficacy of this hypothesis, we tested some initial predictions of the 
outcomes this MMR-directed repair might have in hPSCs, particularly in the absence of a 
protective replication stress response. 
1. MMR directed recognition of lesions generated by MNNG exposure should lead to increased 
accumulation of MMR proteins on damaged chromatin.  
2. The unwinding of DNA by helicases uncoupled from replicative DNA polymerase at forks 
stalled by MMR-direct repair would lead to ssDNA accumulation ahead of stalled forks. 
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3. In the absence of a protective replication stress response, stalled forks would be vulnerable 
to collapse and breakage leading to DSB formation. 
4. DSB repair pathways might be engaged to counteract DSB formation. Consequentially, 
inhibition of these repair pathways should increase sensitivity of hPSCs to alkylation damage. 
 
II. RESULTS 
MMR proteins associate with MNNG-damaged chromatin 
As stated previously, exposure of hPSCs to the alkylating agent, MNNG, induces rapid 
MMR-dependent apoptosis. Replication across MeG lesions generates MeG/T lesions that are 
recognized by MMR proteins (Duckett, Drummond et al. 1996, Mastrocola and Heinen 2010). We 
therefore assessed if alkylation damage exposure induced recruitment of MMR proteins to 
damaged chromatin. Chromatin extracts isolated from H1 hESCs treated with MNNG for 4 h 
showed increased accumulation of the MMR proteins MSH2 and MLH1 onto chromatin in 
response to MNNG treatment. This indicated that MMR proteins associate with MNNG-damaged 
DNA (Fig. 2-6). 
 
MNNG treated hPSCs accumulate ssDNA gaps  
 In-vitro studies suggest that MMR proteins initiate lesion processing at MeG/T mismatches 
culminating in repetitive cycles of futile repair (Kaina, Ziouta et al. 1997). However, the impact of 
these futile repair cycles on replication forks encountering MeG lesions remains unclear. We 
therefore assessed if MMR mediated repair at MeG lesions impacted replication forks. If repair 
across MeG lesions interrupts replication fork progression, we predicted that ssDNA stretches 
would accumulate from the uncoupling of DNA polymerase from the replicative helicase at stalled 
forks. To this end, a native BrdU assay was used to assess ssDNA accumulation in YK26 cells 
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Fig. 2-6. MNNG treatment increases association of MMR proteins with damaged chromatin. 
Immunoblot of chromatin enriched fractions prepared from H1 hESCs treated with 2 µM MNNG 
for 4 h using antibodies against MSH2 or MLH1. Histone H3 is included as a loading control. 
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exposed to MNNG. YK26 were grown in the presence of the thymidine analog 5-bromo-2′-
deoxyuridine (BrdU) for 24 h to label all cellular DNA. After treatment with MNNG for 4 h, 
immunofluorescence analysis was performed under non-denaturing conditions. Under these 
conditions, an antibody to BrdU can only access BrdU epitopes in ssDNA stretches. Thus, the 
observed increased nuclear BrdU signals upon MNNG treatment (Fig. 2-7A, 7B) was indicative 
of ssDNA accumulation, indicative of replication fork disruption (Raderschall, Golub et al. 1999, 
Rubbi and Milner 2001).  
 
Unlike cancer cells, MNNG treatment induces rapid double strand break accumulation in 
hPSCs.  
Although, the accumulation of ssDNA in MNNG treated iPSCs suggested the presence of 
fork disruption, we previously reported that Chk1 is not activated under these conditions (Lin, 
Gupta et al. 2014). Under replication stress conditions the activation of an ATR-Chk1 signaling is 
essential for protection of stalled forks and viability (Couch, Bansbach et al. 2013, Toledo, 
Altmeyer et al. 2013, Zeman and Cimprich 2014). hPSCs fail to activate ATR-Chk1 signaling when 
treated with agents that block replication forks and undergo rapid apoptosis (Desmarais, 
Hoffmann et al. 2012). Therefore, if cells were experiencing MNNG induced replication stress, we 
hypothesized the absence of this signaling would cause breakage and endonucleolytic cleavage 
of stalled forks. DNA damage accumulation was assessed in YK26 and H1 cells 4 h after MNNG 
treatment by staining for phosphorylation of histone variant H2AX (γH2AX), a DNA damage 
marker indicative of replication stress and DSBs (Sharma, Singh et al. 2012). MNNG treatment 
increased number of γH2AX foci in both hPSCs with approximately 70% of cells containing >10 
γH2AX damage foci (Fig. 2-8A, 8B). Concurrently, exposure to MNNG for just 4 h induced 
phosphorylation of RPA at Ser 4/Ser 8 and Thr 21 markers of fork collapse and DSB formation, 
in YK26 and H1 hPSCs (Fig. 2-8C) (Sirbu, Couch et al. 2011, Toledo, Altmeyer et al. 2013). 
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Fig. 2-7. ssDNA stretches accumulate in hPSCs in response to MNNG treatment  
(A) Immunofluorescence imaging of BrdU (green) under non-denaturing conditions from YK26 
cells grown in BrdU (10 µM) containing media for 24 hours prior to treatment with 2 µM MNNG 
for 4 hours. Nuclei are counterstained with DAPI (blue). Nuclear BrdU signals represent regions 
of ssDNA. (B) Images in (A) were quantitated and normalized average nuclear BrdU intensity 
from one representative experiment is shown. Error bars represent S.E.M. (n > 100).    
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Fig. 2-8. MNNG induces double strand break accumulation in hPSCs is hyper accelerated.  
(A): Immunofluorescence imaging of DSB marker γH2AX in YK26 and H1 hPSCs 4 h after 
treatment with MNNG. Nuclei are counterstained with DAPI. (B) Quantitation of percentage of 
cells in (A) with >10 γH2AX (C) Immunoblot of pRPA (S4/S8), pRPA (T21) and RPA in YK26, H1 
and HeLa cells harvest immediately or 20 h after exposure to MNNG for 4 h.   
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Furthermore, induction of this DSB marker in Hela cells was observed only 20 h after the initial 
4h MNNG exposure (Fig. 2-8C). The latter is consistent with pervious reported MMR-dependent 
DSB induction in the second S phase after damage exposure (Stojic, Mojas et al. 2004, Mojas, 
Lopes et al. 2007). These results suggested exposure of hPSCs to alkylation damage leads to 
accelerated DSBs formation. 
 
MNNG induced DSB formation is accompanied by the activation of a MMR dependent DSB 
damage response in hPSCs. 
DNA damage sensing kinases, ATM and DNA-PKcs, respond to DSBs formed by various 
genotoxic agents and orchestrate a DSB damage response (Chanoux, Yin et al. 2009). Upon 
activation, ATM is autophosphorylated at Ser 1981 while DNA-PKcs is phosphorylated at Thr 
2609 (Chan, Chen et al. 2002, Douglas, Sapkota et al. 2002, Bakkenist and Kastan 2003, Chen, 
Chan et al. 2005, Cui, Yu et al. 2005, Yajima, Lee et al. 2006).  These phosphorylation events are 
crucial to coordinating access of DSBs to repair factors (Ding, Reddy et al. 2003, Block, Yu et al. 
2004, Reddy, Ding et al. 2004, Cui, Yu et al. 2005, So, Davis et al. 2009). As MNNG-induced 
γH2AX foci formation and phosphorylation of RPA at Ser 4/Ser8 in hPSCs, we assessed the 
activation of these upstream DNA damage sensing kinases. We found that in H1 cells, MNNG 
treatment induced phosphorylation of ATM at Ser 1981, albeit it was part of a faster migrating 
form of ATM with a corresponding decrease in full length ATM levels (Fig. 2-9A). This cleavage 
event of ATM is proposed to facilitate apoptosis, preventing DNA damage signaling ensuing from 
the extensive DNA fragmentation that accompanies apoptosis (Smith, d'Adda di Fagagna et al. 
1999, Wang, Pabla et al. 2006). We also observed damage induced  phosphorylation on DNA-
PKcs at Thr2609 in H1 cells (Fig. 2-9A). Furthermore, targeted disruption of endogenous MSH2 
genes in H1 cells, creating MSH2-/- H1 cells (KO1 and KO2), alleviated the activation of these 
damage kinases in response to MNNG (Fig. 2-9A). Also, pretreatment of H1 cells with a small  
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Fig. 2-9. MNNG induces a ATM and DNA-PKcs dependent double strand break signaling.  
(A) Immunoblot of pATM (Ser 1981), ATM, pDNA-PKcs (Thr 2609) and DNA-PKcs in WT and 
MSH2-/- (KO1 and KO2) H1 hESCs after treatment with 2 µM MNNG for 4 h. (B) Immunoblot of 
pRPA (S4/S8) and RPA in H1 hESCs treated with 2 µM MNNG for 4 h in the presence of inhibitors 
to ATR (VE-821; 10 µM), ATM (KU-5593; 100 µM) or DNA-PKcs (NU-7026; 50 µM). Actin is 
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included as loading control. (C): Immunoblot of γH2AX in H1 hESCs treated with 2 µM MNNG for 
4 h in the presence of inhibitors to ATR (VE-821; 10µM), ATM (KU-5593; 100 µM) or DNA-PKcs 
(NU-7026; 50 µM). Actin is included as loading control.  
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Fig. 2-10. ATM and DNA-PKcs orchestrate repair of MNNG induced double strand breaks 
in hPSC. 
(A) Survival of WT and MSH2-/- (KO1 and KO2) H1 hESCs treated with increasing concentrations 
of 2 µM MNNG for 4 h in the presence or absence of inhibitors to ATM (KU-5593; 100 µM) or 
DNA-PKcs (NU-7026; 50 µM). Percentage cell survival measured by MTT assay immediately 
following treatment. (B) Immunofluorescence imaging of DSB marker γH2AX and DSB repair 
factor 53BP1 in YK26 iPSCs 4 h after treatment with 2 µM MNNG. Nuclei are counterstained with 
DAPI. 
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molecule inhibitor to ATM and DNA-PKcs kinase activity decreased phosphorylation of RPA (Fig. 
2-9B), consistent with RPA’s role as a downstream target of these damage kinases. However, 
inhibition of no single kinase could sufficiently decrease γH2AX signals in MNNG treated cells 
(Fig. 2-9C). This suggests that both ATM and DNA-PKcs might function redundantly to signal 
DSB formation. Thus, MNNG induces ATM and DNA-PKcs activate DSB signaling in a MMR-
dependent manner.    
Once activated, ATM and DNA-PKcs can initiate activation and recruitment of downstream 
repair factors (Summers, Shen et al. 2011). If they are responsible for promoting repair of MMR 
dependent, MNNG-induced DSBs, then inhibition of ATM and DNA-PKcs kinase activity would 
exacerbate cell death. To test this, cell survival in hESCs pretreated with small molecule inhibitors 
to ATM and DNA-PKcs was determined after MNNG treatment. We observed a further 
enhancement of the dose dependent cell death of WT H1 cells to MNNG (Fig. 2-10A). Meanwhile, 
ATM and DNA-PKcs kinase inhibitors had little effect on the viability of MNNG treated MSH2-/- H1 
cells (KO1 and KO2) (Fig. 2-10A). Conjointly, we observed recruitment of DSB repair factor, 
53BP1 to MNNG induced γH2AX foci (Fig. 2-10B). These results suggested that increased 
sensitivity of WT hESCs to MNNG treatment following inhibition of ATM and DNA-PKcs implied 
attempted repair of MNNG induced DSBs.   
The rapid accumulation of secondary damage in the form of ssDNA and DSBs in hPSCs 
strongly argued in support of the role of MMR directed processing of MeG/T mismatches rather 
than formation of a MMR-directed signaling module. More importantly, these outcomes closely 
mirrored those observed upon the inhibition of ATR-Chk1 replication stress signaling in 
transformed cells experiencing hindrances to fork progression (Couch, Bansbach et al. 2013, 
Toledo, Altmeyer et al. 2013, Zeman and Cimprich 2014). Based on these initial findings in 
hPSCs, we aimed to ascertain the role of the MMR-directed response to alkylation damage as a 
replication stress inducer. To this end, we defined and investigated three endpoints that would be 
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crucial to implicate the MMR-directed response to alkylation damage as a replication stress 
inducer 
1. MMR-directed repair of MeG/T lesions affects replication fork progression. 
2. This activates ATR-Chk1 signaling, facilitating delayed yet coordinated completion of DNA 
replication.   
3. Inhibition of this signaling amidst MMR-directed replication stress induction accelerates DNA 
damage accumulation and sensitivity to alkylation damage.  
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CHAPTER 3 
 
ATR-CHK1 ACTIVATION MITIGATES REPLICATION STRESS CAUSED BY MISMATCH 
REPAIR DEPENDENT PROCESSING OF DNA DAMAGE 
Gupta D., Lin B., Cowan A. and Heinen C. D. 
Proc Natl Acad Sci U S A. 2018 February 13; 115 (7): 1523-1528 
 
I. ABSTRACT 
The mismatch repair pathway (MMR) is essential for removing DNA polymerase errors 
thereby maintaining genomic stability. Loss of MMR function increases mutation frequency and 
is associated with tumorigenesis. However, how MMR is executed at active DNA replication forks 
is unclear. This has important implications for understanding how MMR repairs O6-
methylguanine/thymidine (MeG/T) mismatches created upon exposure to DNA alkylating agents. 
If MeG/T lesion recognition by MMR initiates mismatch excision, the reinsertion of a mismatched 
thymidine during resynthesis could initiate futile repair cycles. One consequence of futile repair 
cycles might be a disruption of overall DNA replication in the affected cell. Herein, we show that 
in MMR-proficient HeLa cancer cells, treatment with a DNA alkylating agent slows S-phase 
progression, yet cells still progress into the next cell cycle. In the first S-phase following treatment 
they activate ataxia telangiectasia and Rad3-related (ATR)-Checkpoint Kinase 1 (Chk1) signaling, 
which limits DNA damage, while inhibition of ATR kinase activity accelerates DNA damage 
accumulation and sensitivity to the DNA alkylating agent. We also observed that exposure of 
human embryonic stem cells to alkylation damage severely compromised DNA replication in a 
MMR-dependent manner. These cells fail to activate the ATR-Chk1 signaling axis, which may 
limit their ability to handle replication stress. Accordingly, they accumulate double strand breaks 
and undergo immediate apoptosis. Our findings implicate the MMR-directed response to 
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alkylation damage as a replication stress inducer, suggesting that repeated MMR processing of 
mismatches may occur that can disrupt S-phase progression.  
 
II. SIGNIFICANCE:   
MMR mediated mismatch correction has largely been recapitulated in the test tube using 
mismatch containing DNA substrates. However, a long-standing question remains: how does 
MMR respond to MeG/T mismatches caused by alkylation damage and does this affect cellular 
replication forks. We demonstrate that MMR-mediated processing of MeG/T mismatches creates 
replication stress, perhaps due to iterative futile repair cycles that affects DNA replication. 
Activation of an ensuing ATR-Chk1 mediated replication stress response becomes important for 
mitigating DNA damage accumulation and prolonging cell survival. This study provides evidence 
that MMR processing may disturb replication forks encountering alkylation damage, which has 
important implications for sensitivity to DNA alkylating agents and for the MMR mechanism. 
 
III. INTRODUCTION 
 The DNA mismatch repair (MMR) pathway repairs mismatches made by the DNA 
polymerase, and thus is essential for genomic stability (Modrich 2006). Germline mutations in 
MMR genes cause the colorectal cancer predisposition syndrome Lynch syndrome, while 10-40% 
of spontaneous colorectal and other cancers also lose MMR function (Lynch, Snyder et al. 2015). 
In addition to repairing mismatches, MMR also plays a role in the cellular response to certain 
forms of DNA damage (Li, Pearlman et al. 2016). For example, treatment of MMR-proficient cells 
with SN1 DNA alkylating agents leads to decreased growth and increased cell death compared to 
MMR-deficient cells (Li, Pearlman et al. 2016). How MMR contributes to this response remains 
unresolved. SN1 alkylating agents create O6-methylguanine (MeG) lesions, which get mispaired 
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with thymidine in S-phase. MMR proteins respond to MeG/T mismatches immediately, however, 
these cells arrest in the G2-phase of the subsequent cell cycle (Li, Pearlman et al. 2016). Two 
models have been proposed to explain these results. One model suggests that recognition of 
MeG/T by the MMR proteins triggers excision of the thymidine-containing strand (Li, Pearlman et 
al. 2016). However, persistence of the MeG on the template strand leads to MeG/T resynthesis, 
initiating iterative futile repair cycles (York and Modrich 2006). How these futile cycles are 
resolved such that the cells continue into a second cell cycle is not clear. Persistent single 
stranded gaps remain after MMR activity that are proposed to become double strand breaks 
(DSB) in the next S-phase, causing the G2 arrest (Mojas, Lopes et al. 2007). A second model 
suggests that the MMR proteins recognize MeG/T and directly recruit proteins involved in signaling 
cell cycle arrest such as Ataxia telangiectasia and Rad3-related (ATR), Ataxia telangiectasia 
mutated (ATM), and the checkpoint kinases Chk1 and Chk2 (Li, Pearlman et al. 2016). As the 
MMR proteins respond to MeG/T in the first S-phase, it is unclear why cell cycle arrest does not 
occur until the second cell cycle after MeG/T formation (Mastrocola and Heinen 2010). Improved 
understanding of the cellular response in the first S-phase following MMR recognition of MeG/T 
lesions may help resolve these questions.   
 Interestingly, we recently reported that human pluripotent stem cells (hPSCs) underwent 
extensive apoptosis within the first S-phase after alkylation damage (Lin, Gupta et al. 2014). This 
immediate response appeared to conflict with the futile cycle model leading us to consider 
whether direct signaling was occurring. However, we noted that hPSCs failed to activate Chk1 or 
Chk2, which are key regulators of the MMR-dependent damage response in human cancer cell 
lines. An earlier study suggested that hPSCs may lack a replication stress response and, as a 
result, are extremely sensitive to replication fork perturbations (Desmarais, Hoffmann et al. 2012). 
We therefore hypothesized that MMR processing of MeG/T lesions might be impeding DNA 
replication progression resulting in replication stress that would be detrimental to hPSCs. If true, 
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then MMR processing of MeG/T lesions might also induce a replication stress checkpoint in 
transformed cell models capable of evoking such a response. In this study, we used human 
embryonic stem cells (hESCs) and HeLa cervical cancer cells to explore the effect of MMR 
processing of MeG/T lesions on DNA replication. We find that alkylation damage disrupts DNA 
replication and produces hallmarks of replication stress in hESCs, while in transformed cells an 
S-phase checkpoint is activated which prevents replication fork collapse and prolongs survival.  
 
IV. MATERIALS AND METHODS 
Cell Culture.  
hESCs (H1) (obtained from the WiCell Research Institute) were cultured under feeder free 
conditions on growth factor reduced Matrigel (Corning®, 356231) coated tissue culture plates in 
hESC media (Peprotech, PeproGrow hESC, BM-hESC-500) and passaged by microdissection 
every 4-6 days. For experiments, hESCs were passaged using StemPro® Accutase® Cell 
Dissociation Reagent (Gibco™, A11105-01) (37˚C, 5-7 min) and equal cell numbers were seeded 
on Matrigel coated plates in media containing ROCK inhibitor (Selleck Chemicals, S1049, 10 µM). 
Next day, media was replaced with fresh media without ROCK inhibitor. Cells treatments were 
performed 3-4 days after passaging.  HeLa cells were grown in Dulbecco's Modified Eagle 
Medium (DMEM, Invitrogen) containing 10% fetal bovine serum (FBS, Gibco).  
MSH2 knockout hESCs were derived using Clustered Regularly Interspaced Short 
Palindromic Repeats (CRISPR)/Cas9 gene targeting. A guide RNA targeting the first exon of 
MSH2 (GCCGAAGGAGACGCTGCAGT), designed using the online resource crispr.mit.edu, was 
cloned into PX330 (Addgene plasmid #42230). A targeting vector containing MSH2 homology 
arms PCR amplified from H1 genomic DNA was cloned into vector pLCA.66/2272 (Addgene 
plasmid #22733) which contains a loxed cassette acceptor with two tandem heteromeric lox sites 
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flanking PGK-puΔtk and EM7-neoR selection cassettes. Although the acceptor cassette was not 
utilized in this study, it was used to disrupt Exon 1 of MSH2. The acceptor cassette was subcloned 
into a PGK-DTA backbone to provide a negative selection marker (Addgene plasmid #13440).  
10 μg of guide RNA and 40 μg of targeting vector were electroporated into H1 hESCs using the 
Bio-Rad Genepulser xcell.  Cells were plated on DR4 mouse embryonic fibroblasts and after 3 
days underwent puromycin (1 μg/mL) selection. Isolated individual surviving colonies were 
genotyped by long-range PCR and targeting was confirmed by Sanger sequencing. Sequencing 
indicated that both alleles were targeted by Cas9 and the acceptor cassette was introduced within 
one allele while the second allele contained insertions and/or deletions that disrupted the reading 
frame due to repair by non-homologous end joining.  
 To generate the MSH2 knockout HeLa cells using (CRISPR)/Cas9 gene the above-
mentioned guide RNA sequence was cloned into the vector Px459V2.0 (Addgene plasmid # 
62988). HeLa cells were transfected with 4 ug of the vector DNA expressing the guide RNA, the 
Cas9 cDNA and a puromycin resistance three days after seeding at a density of approximately 
70% using Lipofectamine® 2000 Reagent (Invitrogen™,11668019) as per manufactures 
instructions. The DNA-lipid complexes were incubated with cells for 6 h after which 1 ml of DMEM 
containing 10% FBS, Gibco was added. Next day, cells were transferred to a 10 cm dish and 
underwent selection in media containing 1 μg/mL puromycin. Hotshot PCR was performed on 
each of the surviving clones (Fwd primer – AGTAGCTAAAGTCACCAGCGTGC and Rev primer 
– CATGTACTTGATCACCCCCTGG) and positive clones were identified using a restriction 
enzyme screen to determine formation of insertions or deletions at the Cas9 cleavage site. Clones 
identified with a positive PCR screen were further screened by Western blot to check for loss of 
MSH2 protein expression.   
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Chemicals.   
N-methyl-N’-nitro-N-nitrosoguanidine (MNNG) (National Cancer Institute Chemical 
Carcinogen Reference Standard Repository; CAS: 70-25-7) and O6-Benzylguanine (O6BG; 
Sigma; B2292) were dissolved in DMSO and stored at −20°C. Inhibitors to ATR (ATRi) (VE-821), 
ATM (ATMi) (KU-5593) and DNA-dependent protein kinase (DNA-Pkcsi) (NU-7026), and small 
molecule inhibitor, pifithrin-μ (PFT-μ), purchased from Selleck Chemicals were dissolved in 
DMSO and stored at −80°C. These were used at the following concentrations: MNNG: 2 μM, 
except in case of MTT assay; O6BG: 25 μM; ATR (VE-821): 10 µM; ATM (KU-5593): 100 µM; 
DNA-PK (NU-7026): 50 µM. MNNG treatments involved a 2 h pretreatment and continual 
maintenance in O6BG containing media until point of harvest.  
 
Cell Synchronization, Cell Cycle Analysis and 3-(4,5-dimethylthiazol-2-yl)-2,5-
diphenyltetrazolium bromide (MTT) Assay.  
hESCs pretreated with O6BG for 2 h were treated with MNNG for 4 h. Cells were washed 
with phosphate buffered saline (PBS) and fresh medium containing O6BG was added. 20 h later 
hESCs were harvested for cell cycle analysis. For cell synchronization at G2/M, HeLa cells were 
grown in 300 ng/mL nocodazole for 16 h, detached by mechanical shake-off, washed three times 
with PBS and re-plated in fresh medium without nocodazole. After 5 h, 25 μM O6BG was added. 
After 2 h, cells were treated with 2 μM MNNG and/or ATRi and harvested at different time points 
for cell cycle analysis. hESCs and HeLa cells harvested using StemPro® Accutase® and Trypsin-
EDTA (Gibco) respectively. The cells were washed with PBS and fixed overnight with chilled 70% 
ethanol at -20˚C. Fixed cells were washed with PBS and incubated with propidium iodide (20 
μg/mL) and RNase A (200 μg/mL) for 30 min at 37°C. After filtration, cell suspensions were 
analyzed using a LSRII flow cytometer (BD Biosciences).  
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For studies in hESCs, cells were pretreated with O6BG and incubated with increasing 
concentrations of MNNG (0.1, 0.2, 0.5, 1 and 2 μM) and corresponding inhibitor in the presence 
of O6BG for 4 h. Cell viability was assessed 20 h later following continued incubation in media 
containing the corresponding inhibitors. For studies in HeLa cells, cell survival was assessed at 
72 h in cells treated with 2 μM MNNG and/or ATRi in the presence of O6BG for 16 h. Cell viability 
was determined using Vybrant® MTT Cell Proliferation Assay Kit (V-13154) as per manufactures 
instructions. 
 
Total Cell Extracts and Western Blotting.  
Total cell extracts were prepared as described in (15). Briefly, harvested cells were lysed 
in ice-cold RIPA buffer containing protease inhibitors for 45 min at 4˚C and centrifuged at 16,000 
g for 10 min. Supernatants were collected as total cell extracts. Equal protein concentrations of 
cell extracts were separated by denaturing SDS-PAGE, transferred onto a PVDF membrane and 
Western blot analysis was performed. Antibodies included: Cell signaling:  ATR (#2790), p-ATR 
(#2853), p53 (#9282), p-p53-Ser 15 (#9284), p-Chk-Ser 345 (#2341), Chk1 (#2345), pChk2-Thr 
68 (#2661), Chk2 (#2662) ; Bethyl: MLH1 (550838), MSH6 (A300-023A), PMS2 (556415), RPA-
S4/S8 (A300-245A), RPA-S33 (A300-246A) p-Chk1-Ser 317 (A304-673A); Sigma-Aldrich: Actin 
(A5060); Calbiochem: RPA (NA19L), MSH2 (NA27); EMD Millipore: γ-H2AX (05-636). 
 
Immunofluorescence and Image Analysis.  
hESCs were plated on Matrigel-coated Thermanox™ Cell Culture Cover Slips (Nunc™, 
174985). To detect DNA synthesis, cells were treated with or without MNNG in the presence of 
5-ethynyl-2′-deoxyuridine (EdU) (10 µM). After 4 h, EdU incorporated into DNA was detected 
using the Click-iT® Plus EdU Alexa Fluor® 647 Imaging Kit (Molecular Probes, C10640) and 
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further processed for immunofluorescence analysis. To assess 53BP1 and Rad51 foci formation 
in hESCs, cells were treated with MNNG for 4 h and processed for immunofluorescence analysis. 
To assess cleaved-caspase-3, hESCs were treated with MNNG for 4 h and fixed immediately, or 
20 h later.  
For detection of ssDNA formation, cells were grown in 5-bromo-2′-deoxyuridine (BrdU) (10 
µM) containing medium for 16 h and then in BrdU free media for 2 h. Subsequently, they were 
treated with O6BG for 2 h, MNNG for 2 h and then fixed 6 h later using chilled methanol for 10 
min at -20°C. Cells were then processed for immunofluorescence analysis as described below.    
To assess 53BP1 foci formation in HeLa cells, cells were treated with MNNG and/or ATRi 
for 14 h and fixed for immunofluorescence analysis. For cleaved-caspase-3 staining HeLa cells 
were treated with MNNG and/or ATRi for 16 h, washed three times with PBS and maintained in 
fresh medium containing O6BG. Cells were processed for immunofluorescence analysis after 72 
h from start of MNNG exposure. To examine replication origin patterns, HeLa cells were 
synchronized in G2/M and harvested as mentioned above. Cells were seeded on glass coverslips. 
After 5 h cells were treated with O6BG for 2 h and then treated with MNNG. 15 min prior to harvest, 
cells were grown in EdU-containing medium to label active origins of replication, followed by 
fixation and processing as described below. 
Following MNNG treatment, cells were fixed with 4% paraformaldehyde (10 min), 
permeabilized with 1% Triton X-100 (10 min) and blocked with 3% goat serum in PBS for 1-2 h at 
room temperature (RT). Cells were incubated with primary antibodies (diluted in 3% goat serum 
in PBS) and then with Alexa Fluor 488 or Alexa Fluor 568 secondary antibodies (Molecular 
Probes) for 1 h each at RT. Antibodies included: γ-H2AX (EMD Millipore; 05-636), BrdU (Santa 
Cruz Biotechnology; sc-32323), Rad51 (EMD Millipore; PC130), 53BP1 (Novus Biologicals: 
NB100-304) cyclin A (Santa Cruz Biotechnology; sc-271645), cleaved-caspase-3 (BD 
Biosciences; 559565). Nuclei were counterstained with 4’,6-diamidino-2-phenylindole (DAPI) or 
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Hoechst-33342 (Life Technologies; 3570), mounted and images were captured using a Zeiss LSM 
780 confocal microscope equipped with a Zeiss Plan-apochromat 63X/1.4 NA oil immersion 
objective or a Nikon Eclipse Inverted Fluorescent microscope. Image analysis was performed 
using MetaMorph.   
 
V. RESULTS  
 
MMR Triggers Rapid Apoptosis in hESCs in Response to MeG Lesions.   
 We previously reported that hPSCs treated with the DNA alkylating agent N-methyl-N’-
nitro-N-nitrosoguanidine (MNNG) undergo rapid apoptosis within the first cell cycle (Lin, Gupta et 
al. 2014). To confirm the MMR-dependence of this response, we used Clustered Regularly 
Interspaced Short Palindromic Repeats (CRISPR)/Cas9-mediated gene targeting to disrupt both 
alleles of the endogenous MMR gene MSH2 in H1 hESCs. The knockout cells lost MSH2 protein 
expression and displayed a decrease in its obligate partner MSH6 (Marra, Iaccarino et al. 1998) 
(Fig. 3-1A). MMR-proficient wild-type (WT) hESCs treated for 20 h with MNNG displayed a large 
fraction of cells with sub-G1 DNA content in cell cycle profiles as well as increased cleaved-
caspase-3 staining, both indicative of apoptotic induction (Fig. 3-1B, C). In contrast, this response 
was largely absent in two independent MSH2 knockout clones (KO1, KO2) (Fig. 3-1B, C). To 
assess if this result was in response to MeG lesions, MNNG sensitivity was examined in the 
presence or absence of O6-Benzylguanine (O6BG), a pseudo-substrate-based inhibitor of 
methylguanine methyltransferase (MGMT), which normally removes MeG lesions from DNA 
(Dolan, Roy et al. 1998). In the presence of O6BG, MNNG induced a dose- dependent decrease 
in cell survival of WT hESCs while viability of KO1 cells was only modestly affected (Fig. 3-1D). 
In the absence of MGMT inhibition, however, sensitivity to MNNG was partially alleviated only in  
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Fig.3-1. Recognition of MNNG induced MeG lesions by MMR proteins triggers a rapid 
apoptotic response in hESCs.  
(A) Immunoblot of mismatch repair proteins MSH2, MSH6 and MLH1 confirming knock-out of both 
endogenous MSH2 alleles in two independent MSH2 KO clones, KO1 and KO2, created by 
CRISPR/Cas9 gene targeting. Actin is included as a loading control. (B) Representative cell cycle 
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profiles as measured by flow cytometry at 24 h of WT, KO1 and KO2 hESCs treated with 2 μM 
MNNG for first 4 h. Encircled are cells with sub-G1 DNA content indicative of apoptosis. (C) 
Immunostaining and confocal imaging for cleaved-caspase-3 of WT, KO1 and KO2 hESCs fixed 
immediately (0 h) or 20 h after treatment with 2 μM MNNG for 4 h. Nuclei are counterstained with 
DAPI. Scale bars: 20 μm. (D) Percentage cell survival after 24 h of WT and KO1 hESCs treated 
with increasing concentrations of MNNG for the first 4 h and in the presence or absence of O6BG 
using the MTT assay. All experiments were performed in triplicate. 
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WT hESCs. These results indicate that MMR dependent recognition of MeG lesions in hESCs 
induces apoptosis in the first cell cycle. 
 
MMR Processing of MeG/T Lesions Affects DNA Replication Leading to DNA Damage 
Accumulation.  
To determine how MeG lesions lead to MMR-specific cytotoxicity in hESCs we assessed 
the impact of MMR activity on replication forks. We predicted that repair across MeG lesions might 
interrupt replication fork progression, uncoupling the DNA polymerase from the replicative 
helicase resulting in ssDNA stretches (Byun, Pacek et al. 2005). To test this, the thymidine analog 
5-bromo-2′-deoxyuridine (BrdU) was added to hESCs for 16 h to label all cellular DNA prior to 
MNNG treatment for 2 h and harvesting 6 h later. Immunofluorescence analysis under non-
denaturing conditions detects BrdU epitopes accessible only in ssDNA stretches (Rubbi and 
Milner 2001). MNNG exposure led to increased nuclear BrdU signals in WT hESCs indicative of 
ssDNA accumulation (Fig. 3-2A, 2B). These signals were significantly attenuated in MSH2 KO 
hESCs (Fig. 3-2A, 2B). Both control and MNNG-treated cells showed cytoplasmic BrdU signals 
previously reported to arise from ssDNA stretches in mitochondrial DNA (Schlegel, Jodelka et al. 
2006). As ssDNA is vulnerable to endonucleolytic cleavage into DSBs, we stained for the DNA 
damage marker, γH2AX which can be indicative of DSBs and replication stress (Sharma, Singh 
et al. 2012, Sirbu, Couch et al. 2012). Increased γH2AX foci were observed in hESCs within 4 h 
of MNNG treatment (Fig. 3-3A). Concurrently, DSB repair factors Rad51 and 53BP1 involved in 
homologous recombination or non-homologous end joining, respectively, accumulated at sites of 
MNNG-induced γH2AX foci only in WT hESCs (Fig. 3-4A-4D). If this damage resulted from MMR 
processing of MeG/T lesions, we predicted that its appearance would only occur at replication sites 
active during MNNG exposure (Altshuler, Hodes et al. 1996). To test this, we treated cells with 
MNNG in the presence of a thymidine analog 5-ethynyl-2′-deoxyuridine (EdU) to mark actively 
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replicating regions. We found γH2AX foci were observed only in cells that incorporated EdU 
during MNNG exposure mirroring DNA replication patterns (Fig. 3-3B). Notably, although damage 
accumulated at sites of DNA replication, MNNG treatment markedly reduced total EdU 
incorporation in WT hESCs indicating that overall DNA replication was severely compromised 
(Fig. 3-3C, 5A). These responses were MMR dependent, as MNNG-treated KO1 and KO2 cells 
accumulated fewer γH2AX foci with less disruption to DNA replication (Fig. 3-3C, 5A and 5B). 
γH2AX foci that did form in KO cells may have resulted from infrequent collisions of replication 
forks with base excision repair intermediates from other MNNG generated adducts (Ensminger, 
Iloff et al. 2014). Overall, these results suggest that MMR processing at MeG adducts compromises 
DNA replication and creates replication stress. 
Replication stress can activate a protective ATR-Chk1 signaling axis that prevents 
replication fork collapse (Zeman and Cimprich 2014). The formation of DSBs in replicating hESCs 
treated with MNNG, however, suggested this replication stress response was lacking. We 
examined activation of ATR-Chk1 signaling in MNNG-treated hESCs by measuring 
phosphorylation of ATR at Ser 428, of the ssDNA binding replication protein A (RPA) at Ser 33 
and of Chk1 at Ser 345 (Lopez-Girona, Tanaka et al. 2001, Olson, Nievera et al. 2006, Liu, 
Shiotani et al. 2011). None of these sites appeared phosphorylated following 4 h of MNNG 
treatment; a timepoint that likely captures events in the first S-phase after treatment and at which 
point γH2AX is already observed (Fig. 3-3D, 6A). Instead, we saw phosphorylation of RPA at S4 
and S8 residues, markers of fork collapse, in WT hESCs, which are reduced in the KO hESCs 
(Fig. 3-6B). The failure to activate this ATR-Chk1 signaling response was also accompanied by 
rapid phosphorylation and stabilization of the tumor suppressor protein p53 in WT hESCs (Fig. 3-
3E). Loss of MSH2 alleviated the levels of p53 phosphorylation in response to MNNG (Fig. 3-3E). 
To test if p53 activation induced the apoptotic response, we blocked p53 translocation to 
mitochondria using a small-molecule inhibitor pifithrin-µ (Strom, Sathe et al. 2006). Pre-treatment  
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Fig. 3-2. MMR-directed repair in MNNG treated hESCs causes accumulation of ssDNA 
gaps.  
(A) WT and KO1 hESCs with BrdU labeled parental DNA treated with 2 μM MNNG for 2 h. ssDNA 
gap formation was assessed 6 h later by immunostaining with BrdU antibody under non-
denaturing conditions. Nuclei are counterstained with DAPI. Experiments performed in triplicate. 
Scale bars: 10 µm. (B) Quantitation of average nuclear BrdU intensity in MNNG treated WT and 
KO1 hESCs from one representative experiment (n>190); (*, **) P ˂ 0.0001, Mann-Whitney test.  
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Fig. 3-3. Processing of MeG/T lesions by MMR affects DNA replication, DSB formation and 
activation of a p53-dependent apoptosis.   
(A) Immunostaining for DSB marker γH2AX in WT hESCs treated with 2 μM MNNG for 4 h. Scale 
bars: 10 μm. (B) Immunostaining of γH2AX in WT hESCs treated with 2 μM MNNG for 4 h in the 
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presence of EdU (10 μM). EdU incorporation detected using click chemistry. (C) Immunostaining 
of γH2AX and EdU incorporation in nuclei of WT, KO1 and KO2 hESCs treated with 2 μM MNNG 
and EdU for 4 h. Scale bars: 10 μm. (D) Immunoblot of pATR (Ser 428), ATR, pChk1 (Ser 345), 
Chk1, pRPA (S33), RPA and γH2AX in WT hESCs treated with 2 μM MNNG for 4 h. Actin used 
as a loading control. (E) Immunoblot of MSH2, MLH1, p-p53 (Ser 15) and p53 in WT, KO1 and 
KO2 hESCs treated with 2 μM MNNG for 4 h. (F) Percentage cell survival of WT hESCs assessed 
using MTT assay in the presence or absence of pifithrin-μ (20 μM) 24 h after treatment with 
increasing concentrations of MNNG for first 4 h. All experiments were performed in triplicate.  
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Fig 3-4. Upon MNNG treatment, homologous recombination (HR) and non-homologous end 
joining (NHEJ) repair factors are recruited to sites of MMR-induced double strand breaks.  
(A) Immunofluorescence and confocal imaging of γH2AX and HR repair factor Rad51 in WT, KO1 
and KO2 hESCs 4 h after treatment with 2 µM MNNG. Nuclei are counterstained with DAPI. Scale 
bars: 10 µm. (B) Immunofluorescence and confocal imaging of γH2AX and NHEJ repair factor 
53BP1 in WT, KO1 and KO2 hESCs 4 h after treatment with 2 µM MNNG. Nuclei are 
counterstained with DAPI. Scale bars: 10 µm. (C) Quantitation of percentage of nuclear area 
positive for Rad51 signal. Results from one representative experiment as described in (A) 
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(n>300); (*, **, ***) P ˂  0.0001, Mann-Whitney test. (D) Quantitation of percentage of nuclear area 
positive for 53BP1 signal. Results from one representative experiment as described in (B) 
(n>250); (*, **, ***) P ˂ 0.0001, Mann-Whitney test. 
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Fig 3-5. MMR-dependent processing of MeG/T lesions in hESCs compromises DNA 
replication and promotes accumulation of double strand breaks. 
(A) Quantitation of average nuclear EdU from one representative experiment as performed in Fig 
2B (n> 150); (*, **, ***) P ˂  0.0001, Mann-Whitney test. (B) Quantitation of average nuclear γH2AX 
intensities in EdU positive cells from one representative experiment as performed in Fig 2B (n> 
150); (*, **, ***) P ˂ 0.0001, Mann-Whitney test. 
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with pifithrin-µ reduced cell death even at the highest MNNG concentrations tested (Fig. 3-3F). 
To confirm that ATR activation did not play a role in this rapid response, we co-treated WT hESCs 
with MNNG and an inhibitor to ATR kinase activity (ATRi) for 4 h. The addition of ATRi had no 
effect on the levels of p53 activation or sensitivity to MNNG at this time point, whereas ATM 
inhibition did affect p53 activation at this early stage (Fig. 3-7A, 7C). As we previously had 
observed ATR activation 24 h after exposure to MNNG (Lin, Gupta et al. 2014), we tested the 
effect of ATRi on p53 activation and/or sensitivity at a later time point. Indeed, addition of ATRi 
decreased p53 activation in MNNG treated hESCs after 24 h as did inhibitors to ATM and DNA- 
dependent protein kinase (DNA-PK) (Fig. 3-7B). At the later time point, though, ATRi in 
combination with MNNG increased cell death compared to MNNG alone (Fig. 3-7C). This later 
activation of ATR may be a response to intermediates of DSB repair, which could explain why 
ATRi increased sensitivity to MNNG at this time point (Jazayeri, Falck et al. 2006, Myers and 
Cortez 2006). Combined, our results suggest that MMR-processing of MeG/T lesions interferes 
with DNA replication but fails to activate an ATR-Chk1-mediated replication stress checkpoint in 
hESCs. Instead, these cells accumulate DSBs, consistent with replication fork collapse, and 
undergo rapid, p53-dependent apoptosis. 
 
DNA Alkylation Damage Leads to ATR-Chk1 Activation in Cancer Cells.  
The effect of MNNG-treatment on DNA replication in hESCs strongly suggested that MMR 
dependent processing of MeG/T lesions induces replication stress. However, evidence of MNNG-
induced replication stress in transformed cell lines has been largely overlooked due to their 
continued progression into the second cell cycle (Mastrocola and Heinen 2010, Li, Pearlman et 
al. 2016). We suspected that differences in ATR-Chk1 activation could contribute to the differential 
responses between these cell types. To this effect, we first assessed if MMR-proficient HeLa 
cancer cells activate Chk1 14 h after MNNG treatment, a time point at which the cells would have 
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Fig 3-6. MNNG induced replication stress in hESCs triggers fork collapse without 
activating ATR kinase in a MMR-dependent manner  
(A) Immunoblot of pATR (Ser 428), ATR, MSH2 and MLH1, in WT, KO1 and KO2 hESCs treated 
with 2 μM MNNG for 4 h. Actin used as a loading control. (B) Immunoblot of MSH2, MLH1, pRPA 
(S4/S8) and RPA in WT, KO1 and KO2 hESCs treated with or without 2 µM MNNG for 4 h. Actin 
is included as loading control.  
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Fig 3-7. ATR kinase activity does not contribute to early apoptotic induction in MNNG 
treated WT hESCs.  
(A) Immunoblot of p-p53 (Ser 15) and p53 in WT hESCs treated with or without 2 µM MNNG for 
4 h in the presence of inhibitors to ATR (VE-821: 10 µM), ATM (KU-5593; 100 µM) or DNA-PKcs 
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(NU-7026; 50 µM). Actin is included as loading control. (B) Immunoblot of p-p53 (Ser 15) and p53 
in WT hESCs treated with or without 2 µM MNNG for 4 h and harvested 20 h later in the presence 
of inhibitors to ATR (VE-821: 10 µM), ATM (KU-5593; 100 µM) or DNA-PKcs (NU-7026; 50 µM). 
Actin is included as loading control. (C) Percentage cell survival of WT hESCs treated with 2 µM 
MNNG for 4 h in the presence or absence of inhibitors to ATR (VE-821: 10 µM). Cell survival was 
measured by MTT assay immediately or 20 h following treatment as described in schemes for (A, 
B). All experiments were performed in triplicate. 
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 only entered a single S-phase. We found that under these conditions Chk1 was phosphorylated 
on Ser 317 and Ser 345; an effect that was abrogated by the addition of ATRi (Fig. 3-8A). We 
also tested the MMR-dependence of this response by using CRISPR-Cas9 gene targeting to 
disrupt the endogenous MSH2 alleles in HeLa cells and observed no activation of Chk1 upon 
MNNG exposure in two independent MSH2 KO clones (Fig. 3-9A). We next investigated if Chk1 
activation induced an intra-S-phase replication checkpoint. HeLa cells synchronized in mitosis 
were released into the cell cycle, treated with MNNG or vehicle control in G1 phase and allowed 
to progress through the cell cycle. Cell cycle profiles of mock-treated cells showed entry and 
completion of the first S-phase by 10 h and 18 h post-release, respectively (Fig. 3-8B). MNNG 
treatment however, delayed progression through S-phase with a significant cell population still in 
S-phase at 18 h (Fig. 3-8B). A salient feature of the intra-S-phase checkpoint is coordinated 
completion of DNA replication thereby mitigating DNA damage accumulation (Blow, Ge et al. 
2011). Within replication factories, ATR-Chk1 mediates activation of dormant replication origins 
adjacent to stalled forks while delaying replication onset within inactive clusters. We therefore 
predicted that MNNG treatment would delay replication onset within replication clusters active late 
in S-phase. To visualize active replication factories, synchronized HeLa cells were pulse-labeled 
with EdU 15 minutes prior to harvest. We observed distinct replication foci patterns that emerge 
from spatio-temporal regulation of DNA replication in S-phase (Fig. 3-8C) (Chakalova, Debrand 
et al. 2005). In control cells in early S-phase (10 h), active DNA replication clusters were observed 
throughout the nucleus. Mid and late S-phase DNA replication patterns were discernable at 14 h 
wherein DNA replication was observed at the nuclear periphery and nucleolar regions. DNA 
replication was completed by 16 h. In MNNG- treated cells, although early S-phase origin 
activation patterns were visible at 10 h, DNA replication continued within these clusters until 16h. 
In addition, activation and completion of DNA replication within mid and late S-phase replication 
factories was delayed to 16 h and 20 h, respectively. MNNG treatment also appeared to reduce 
the percentage of EdU-positive cells suggesting a delayed entry into S-phase. However, careful 
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Fig. 3-8. MNNG treatment in HeLa cells induces an ATR-Chk1 dependent replication stress 
checkpoint that allows delayed, yet coordinated completion of replication.  
(A) Immunoblot of pChk1 (Ser 345), pChk1 (Ser 317) and Chk1 in MMR proficient HeLa cells 
treated with 2 μM MNNG and an ATR inhibitor (ATRi) (10 μM) for 14 h. Actin used as a loading 
control. Experiments were performed in triplicate. (B) Representative cell cycle profiles of HeLa 
cells harvested at indicated times after release from mitotic synchronization and exposed to 2 μM 
MNNG in G1 in the presence or absence of ATRi. Percentage of cells in S phase at 18 h 
quantitated from the cell cycle profiles are: untreated (14.4%), MNNG (39.3%), ATRi (16.6%) and 
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MNNG + ATRi treated (18.4%) (C) HeLa cells treated with 2 μM MNNG as described in B were 
pulsed with EdU 15 min prior to harvest. EdU incorporation marking actively replicating DNA 
clusters was detected using click chemistry. Experiments were performed in duplicate. Scale bars: 
10 μm.  
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Fig 3-9. MMR processing of MNNG induced lesions in HeLa cells activates an ATR-Chk1 
dependent replication stress checkpoint.  
(A) Immunoblot of pChk1 (Ser 345), pChk1 (Ser 317), Chk1, MSH2 and MLH1 in MSH2 WT and 
MSH2 KO (KO1 and KO2) HeLa cells treated with 2 μM MNNG for 14 h. Actin used as a loading 
control. Experiments were performed in triplicate. (B) Overexposure of 10 h time point images in 
Fig 3C to visualize percentage of nuclei positive for EdU incorporation. Arrows point to nuclei that 
are truly negative for EdU incorporation in untreated cells harvested at 10h even at high 
exposures. Arrowheads point to nuclei that appear negative for EdU incorporation at low exposure 
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in MNNG treated cells harvested at 10 h, but are actually positive for EdU at high exposure. Scale 
bars: 10 μm. (C) Quantitation of EdU positive cells from one representative experiment as 
described in Fig. 3C visualized at high exposure. 
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inspection of these cells revealed that the number of Edu-positive cells was only slightly reduced. 
Rather, the intensity of EdU staining was low in many cells consistent with delayed replication 
progression and not delayed S-phase entry (Fig. 3-9B and 9C). These results suggest that MNNG 
treatment induces a replication stress checkpoint in transformed cells that allows delayed, yet 
coordinated completion of replication. 
 
ATR-Chk1 Mitigates DNA Damage Accumulation in Response to MeG–Induced Replication 
Stress.  
In addition to coordinating replication completion, an ATR-Chk1-mediated intra-S-phase 
checkpoint is crucial for protecting stalled forks from collapse and preventing apoptosis (Couch, 
Bansbach et al. 2013, Toledo, Altmeyer et al. 2013, Zeman and Cimprich 2014). We, therefore, 
predicted that inhibiting the ATR kinase in MNNG-treated HeLa cells should cause collapse of 
stalled forks, thereby exacerbating DNA damage accumulation and cell death. To this effect, we 
assessed if ATR-Chk1 signaling slowed S-phase progression of MNNG-treated HeLa cells. HeLa 
cells co-treated with ATRi and MNNG completed their first S-phase by 18 h, a rate comparable to 
that of untreated cells (Fig. 3-8B). We next examined whether ATRi led to increased DSBs in the 
first cell cycle after MNNG treatment by measuring 53BP1 foci formation at 14 h. Using cyclin A 
to identify S and G2 cells, we found that mock treated cells contained 1-5 53BP1 foci when in G1, 
consistent with previously reported baseline endogenous DNA damage levels in transformed cells 
(Fig. 3-10A and B) (Bekker-Jensen, Lukas et al. 2005, Lukas, Savic et al. 2011). However, 53BP1 
foci (> 10 per cell) increased in MNNG-treated G1 nuclei. A G1 specific increase in 53BP1 foci has 
previously been attributed to the sequestration of DNA damage carried forward through mitosis 
into the subsequent cell cycle (Lukas, Savic et al. 2011). Thus, these observed foci may arise 
from unreplicated gaps created by MMR processing of MeG/T lesions during S-phase in cells that 
then progressed to the next G1 during the 14 h experiment (Mojas, Lopes et al. 2007).  
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Fig. 3-10. ATR-Chk1 signaling in the first S phase is crucial to mitigating DNA damage 
accumulation in MNNG treated HeLa cells.  
(A) Immunostaining for 53BP1 and cyclin A, a S/G2 phase marker, in HeLa cells treated with 2 
μM MNNG in the presence or absence of ATRi (10 μM) for 14 h. Arrows point to cyclin A negative 
nuclei with >10 53BP1 foci. Arrowheads point to cyclin A positive nuclei with >10 53BP1 foci. (B) 
Quantitation of percentage nuclei in G1 and S/G2 cell cycle phase with >10 53BP1 foci. ((*, **, 
****) P ≤ 0.01, (***, *****) P ≤ 0.05, Student’s t-test). (C) Immunoblot of pChk2 (Thr 68), Chk2, 
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pRPA (S4/S8) and RPA in HeLa cells treated with 2 μM MNNG in the presence or absence of 
ATRi (10 μM) for 14 h. Actin used as a loading control. (D) Immunostaining for cleaved-caspase-
3 at 72 h in HeLa cells treated with 2 μM MNNG for the first 16 h in the presence or absence of 
ATRi (10 μM). Scale bars: 20 μm. (E) Quantitation of percentage of cells positive for cleaved-
caspase-3 staining (P ≤ 0.01, Student’s t-test). (F) Cell survival assessed using MTT assay at 72 
h in HeLa cells treated with MNNG for the first 16 h in the presence or absence of ATRi (10 μM). 
(P ≤ 0.01, Student’s t-test). All experiments were performed in triplicate. 
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Consequently, the number of MNNG-induced 53BP1 foci was greatly reduced upon MSH2 loss 
(Fig. 3-10B and 11A). In contrast, ATRi addition to MNNG-treated WT cells altered the dynamic 
of 53BP1 foci formation, wherein increased numbers of 53BP1 foci accumulated in cyclin A 
positive S and G2 nuclei (Fig. 3-10A, 10B and 11A). No such increase in 53BP1 foci in cyclin A-
positive S and G2 nuclei was observed in MSH2 KO HeLa cells (Fig. 3-10B and 11A). These 
damage foci therefore may be a consequence of replication forks collapsing due to MMR-induced 
replication stress (Sirbu, Couch et al. 2012, Couch, Bansbach et al. 2013, Toledo, Altmeyer et al. 
2013). Correspondingly, combining MNNG and ATRi in WT cells induced phosphorylation of Chk2 
and RPA at S4/S8 within 14 h, indicative of DSB formation and replication fork collapse 
respectively within the first cell cycle of MNNG exposure (Sirbu, Couch et al. 2012, Couch, 
Bansbach et al. 2013, Toledo, Altmeyer et al. 2013) (Fig. 3-10C). We next determined how 
addition of ATRi during the first cell cycle affected viability of MNNG-treated HeLa cells. We found 
that while cell survival decreased slightly in MNNG treated WT-HeLa cells 72 h after damage 
exposure, addition of ATRi for only the first 16 h of MNNG exposure significantly reduced viability 
as seen by increased cleaved-caspase-3 staining, excessive DNA fragmentation and overall 
decrease in cell number at 72 h (Fig 3-10D-F). The induction of DSB markers and increased 
sensitivity to MNNG in the presence of ATRi were alleviated in both MSH2 KO HeLa clones (Fig. 
3-11B-D). Overall, these results indicate that ATR-Chk1 signaling in the first S-phase after MNNG 
treatment is crucial for limiting DNA damage accumulation and promoting cell survival in the face 
of replication stress caused by MMR-mediated processing of MeG/T lesions.  
 
VI. DISCUSSION 
MMR has long been implicated in eliciting cytotoxicity to SN1 DNA alkylating agents (Li, 
Pearlman et al. 2016). The steps following MeG/T recognition, however, are not entirely clear, 
particularly as MMR-proficient transformed cells undergo G2 arrest only after cells go through two 
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S-phases. Both a direct signaling model, in which MMR proteins directly recruit factors involved 
in signaling cell cycle arrest to damaged DNA, as well as a futile cycle model, in which iterative 
cycles of repair at MeG/T lesions leads to downstream DNA damage that ultimately triggers arrest 
have been proposed (Li, Pearlman et al. 2016). In both models, it is unclear if MMR activity 
coordinates with the replication fork or whether MMR occurs in a post-replication manner leaving 
the passing fork unaffected. If the former, repair events occurring at the fork could lead to fork 
disruption and therefore impair DNA replication. As MMR-proficient cancer cells were shown to 
complete the first S-phase after treatment with DNA alkylating agents, it appeared that DNA 
replication proceeded uninterrupted amidst active MMR (York and Modrich 2006, Mastrocola and 
Heinen 2010, Li, Pearlman et al. 2016). However, our recent observation that hESCs undergo 
rapid MMR-dependent apoptosis directly in the first S-phase following alkylation damage led us 
to re-examine the effects of MMR on the first S-phase more carefully (Lin, Gupta et al. 2014). 
Herein, we observed that MeG lesions generated by MNNG decreased hESC viability within just 4 
h. This was accompanied by increased ssDNA and DSB formation in cells that underwent DNA 
replication. Most strikingly, besides accumulating damage at replication foci, overall DNA 
replication was severely impacted in MMR-proficient hESCs. These results provide evidence that 
the MMR-mediated response to MeG/T lesions indeed affects DNA replication.  
We propose that cancer cells tolerate MMR-mediated disruption to the replication fork via 
activation of an ATR-Chk1-intra-S-phase checkpoint that facilitates continued cell cycle 
progression into the next cell cycle (Fig. 3-12). While the majority of MNNG treated cells will 
ultimately arrest in the next G2 phase, the transient intra-S-phase response likely expands the 
opportunity for some cells to escape this fate. A failure to activate ATR-Chk1 under conditions of 
replication stress has been shown in transformed cells to cause increased ssDNA accumulation 
at stalled forks (Couch, Bansbach et al. 2013, Toledo, Altmeyer et al. 2013, Zeman and Cimprich 
2014). Vulnerable to breakage, these paused forks can collapse, leading to accumulation of lethal  
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Fig 3-11. DNA damage accumulation upon inhibition of ATR-Chk1 signaling in the first S 
phase of MNNG treated HeLa cells is dependent on functional MMR  
(A) Immunostaining for 53BP1 and cyclin A, a S/G2 phase marker, in WT and MSH2 KO1 HeLa 
cells treated with 2 μM MNNG in the presence or absence of ATRi (10 μM) for 14 h. (B) 
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Immunoblot of pChk2 (Thr 68), Chk2, pRPA (S4/S8) and RPA in WT and MSH2 KO (KO1 and 
KO2) HeLa cells treated with 2 μM MNNG in the presence or absence of ATRi (10 μM) for 14 h. 
Actin used as a loading control. (C) Immunostaining for cleaved-caspase-3 at 72 h in WT and 
MSH2 KO (KO1 and KO2) HeLa cells treated with 2 μM MNNG for the first 16 h in the presence 
or absence of ATRi (10 μM). Nuclei are counterstained with DAPI. Scale bars: 20 μm. (D) 
Quantitation of percentage of cells positive for cleaved-caspase-3 staining (P ≤ 0.01, Student’s t-
test). 
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DSBs. We found that chemical inhibition of ATR-Chk1 signaling in MNNG-treated HeLa cells 
resulted in induction of markers of fork collapse and DSBs within the first cell cycle such as 
phosphorylation of RPA and Chk2, respectively, as well as increased S- and G2-phase 53BP1 
foci. In addition, ATR inhibition accelerated sensitivity to MNNG. Given the ability of transformed 
cells to normally cope with replication stress in this way, it is not surprising that the effect of MMR 
processing of MeG/T mismatches on global DNA replication has gone largely unnoticed. In 
contrast, hESCs appear to lack a protective ATR-Chk1 signaling cascade in response to MNNG 
as well as other inducers of replication stress (Desmarais, Hoffmann et al. 2012) and instead 
accumulate ssDNA and DSBs and rapidly apoptose. Thus, the effects of MMR processing of 
MeG/T lesions on global DNA replication are more apparent. The inability of these cells to complete 
DNA replication may stem from an absence of dormant origin firing in response to active forks 
failing to bypass MeG lesions. The apoptotic induction in hESCs is much more rapid compared to 
HeLa cells, a discrepancy which may arise from the primed nature of hESCs to undergo apoptosis 
at the slightest signs of stress (Liu, Guan et al. 2013).  
The MMR-dependent induction of replication stress in response to MeG/T lesions fits nicely 
in the context of the futile cycle model. Repetitive repair cycles may inhibit DNA replication 
progression resulting in fork stalling and, in the absence of ATR-Chk1 activity, fork collapse. 
Alternatively, futile processing at multiple MeG/T lesions may utilize extensive amounts of RPA, 
known to bind to the ssDNA gaps generated during MMR processing (Genschel and Modrich 
2003, Zhang, Yuan et al. 2005). This may require activation of ATR-Chk1 signaling in order to 
prevent RPA exhaustion that has effects on fork stability more globally (Toledo, Altmeyer et al. 
2013). Support for a direct signaling mechanism is less obvious from our results. Despite the early 
cell death in hESCs, we observe a lack of activation after treatment from proteins implicated in 
the direct signaling model such as ATR, Chk1 and Chk2 (Li, Pearlman et al. 2016). This reduced 
damage signaling would seem counterintuitive to the accelerated cell death observed in these  
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Fig. 3-12. Model of the effects of the MMR-directed response to MeG/T lesions on DNA 
replication progression.  
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cells. In HeLa cells treated with MNNG, the cells do not undergo an arrest until the second cell 
cycle after treatment. Thus, a temporal disconnect remains between the initiation of MMR activity 
in the first cell cycle and cell cycle arrest in the next. However, we cannot rule out the possibility 
that the MMR proteins are initiating a direct signaling response in the first S-phase that protects 
HeLa cells initially after treatment to prevent replication fork collapse. This scenario would still 
require an additional function of the MMR proteins to cause the eventual cell cycle arrest that 
occurs in the next G2-phase. What is clear is that ATR-Chk1 signaling is crucial for protecting cells 
from the detrimental effects of DNA replication disruption by MMR processing of alkylation 
damage. Future studies will be required to investigate how MMR proteins communicate with the 
DNA replication machinery to cause this disruption.  
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CHAPTER 4 
 
CONCLUSIONS AND FUTURE DIRECTIONS 
 
Replication across MeG lesions results in formation of MeG/T lesions that are recognized by 
MMR proteins. But the events ensuing lesion recognition have remained elusive. In transformed 
cells, MMR-dependent recognition of MeG/T lesions in the first S phase elicits a permanent G2 
arrest in the subsequent cell cycle and culminates in cell death (Duckett, Drummond et al. 1996, 
Stojic, Mojas et al. 2004, Mastrocola and Heinen 2010, Li, Pearlman et al. 2016). Yet, hPSCs 
activate a MMR-dependent apoptotic response within the first S phase itself (Lin, Gupta et al. 
2014). We therefore aimed to resolve how MMR-dependent MeG/T mismatch recognition could 
yield differential responses/outcomes within these two model systems by ascertaining the effects 
of lesion recognition on the first S phase.   
 
VI. MMR-DIRECTED RESPONSE TO ALKYLATION DAMAGE AS A REPLICATION STRESS INDUCER 
 
In-vitro studies have described MMR-directed excision of the erroneous strand as a crucial 
step for mismatch correction (Kunkel and Erie 2005, Modrich 2006). Yet, how this post replicative 
repair is executed at cellular replication forks is unclear. The interaction of MMR proteins with the 
DNA polymerase processivity factor, PCNA, could suggest a possible linkage between the fork 
and the repair process (Hidaka, Takagi et al. 2005, Mastrocola and Heinen 2010). Amid such a 
coordination, rapid and efficient repair of simple DNA mismatches may not yield a discernable 
impairment to fork progression. Alternatively, repeated cycles of MMR-directed excision and 
MeG/T mismatch resynthesis could disrupt the fork movement. However, these iterative cycles of 
MMR activity caused no observable effects on global DNA replication in transformed cell models 
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(Mojas, Lopes et al. 2007). This suggested that MMR’s interaction with PCNA likely facilitated 
their localization to the fork to enhance mismatch recognition. Additionally, MMR activity was 
inferred to be executed in the wake of the replication fork (Mojas, Lopes et al. 2007). Interestingly, 
we observed that futile repair cycles initiated by MMR in hESCs severely affected DNA replication. 
In this study we provide evidence for a previously unobserved coordination between MMR activity 
and the replication fork. Herein, we define the MMR-directed response to alkylation damage as a 
replication stress inducer based on three measured endpoints 
1. MMR-directed repair of MeG/T lesions affects completion of DNA replication. 
2. Subsequent activation of ATR-Chk1 signaling facilitates delayed yet coordinated 
completion of DNA replication. 
3. Inhibition of ATR-Chk1 signaling amidst this MMR-directed repair accelerates DNA 
damage accumulation and sensitivity to alkylation damage.  
 
When considering the mechanism of MMR-induced replication stress it is important to note 
key distinctions compared to that of other known replication stress inducers. Canonical replication 
stress inducers like aphidocolin and hydroxyurea inhibit DNA-polymerase activity or cause 
nucleotide pool depletion respectively. This causes an acute and rapid inhibition of individual fork 
movement. In DNA fiber labelling assays, this culminates in an abrupt disruption of thymidine 
analogue incorporation and significantly shorter labeled nascent strand DNA stretches compared 
to untreated controls (Merrick, Jackson et al. 2004). The ensuing ATR-Chk1 replication stress 
response inhibits replication initiation within inactive and late firing origin clusters (Ge and Blow 
2010). Additionally, replication factors are redirected to active DNA replication clusters to 
maximize replication completion and minimize ssDNA stretches (Toledo, Altmeyer et al. 2013). 
Even under these conditions, perturbations to fork movement are prominent and new origin firing 
is prevented until favorable conditions are reestablished.  
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Conversely, the subtle effect of MMR activity on fork movement has made studying the 
coordination between MMR and replication machinery particularly difficult. As MMR does not 
affect DNA-polymerase activity directly or via depletion of nucleotide pools, inhibition on fork 
movement is not acute. Rather, DNA fiber labelling assays would likely yield labeled nascent DNA 
strands of varying length depending upon when and if the fork encounters a MeG lesion. Strand 
resynthesis after MMR directed excision would further confound the identification of affected forks. 
Secondly, ATR-Chk1 signaling could coordinate usage of replication factors to complete and 
minimize the effects on global DNA replication (Fig. 4-1). Replication patterns observed in 
synchronized HeLa cells elude to this signaling mediated replication rescue (Fig. 3-8C). Upon first 
entering S-phase, synchronized HeLa cells exposed to alkylation damage exhibit a marked 
decrease in incorporation of the thymidine analogue EdU (Fig. 3-8C). This would suggest that 
MMR-activity affects DNA replication very early in S-phase. However, as ATR-Chk1 signaling is 
established the effect on global DNA replication becomes indiscernible at later time points. 
Dormant origins proximal to stalled forks likely facilitate the delayed completion of DNA 
replication. Thirdly, ATR and Chk1 are key regulators of origin firing even in an unperturbed S 
phase (Cortez 2015, Saldivar, Cortez et al. 2017). Inhibition of Chk1 kinase activity causes 
deregulated origin firing and decreased inter-origin distance in the absence of replication stress 
(Maya-Mendoza, Petermann et al. 2007). Premature activation of late S-phase origin is 
accompanied by increased damage and replication stress accumulation (Syljuasen, Sorensen et 
al. 2005, Rodriguez, Gagou et al. 2008, Gagou, Zuazua-Villar et al. 2010, Toledo, Altmeyer et al. 
2013). These confounding effects of inhibiting ATR-Chk1 signaling in a cancer cell model would 
further affect the ability to investigate the coordination between MMR activity and replication 
machinery (Fig. 4-2).  
Our success in identifying the MMR-directed response to alkylation damage as a 
replication stress inducer is largely attributed to the lack of an ATR-Chk1 replication stress  
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Fig. 4-1. Proposed model by which the activation of an ATR-Chk1 replication stress 
response in transformed cells protects forks stalled by MMR-directed processing of 
alkylation damage while facilitating completion of DNA replication. 
(A) Iterative cycles of MMR-directed processing at forks encountering MeG lesions on the template 
strand disrupts fork progression. (B) MMR-induced fork stalling results in uncoupling of DNA 
helicase from the replication machinery resulting in ssDNA stretches. RPA protects ssDNA 
generated at stalled forks preventing fork breakage. RPA bound to ssDNA recruits DNA 
translocase, SMARCAL1, initiating fork reversal mediated fork protection. Activation of the ATR-
Chk1 replication stress response prevents aberrant fork processing. ATR-Chk1 signaling 
promotes dormant origin firing in the proximity of forks stalled by MMR-directed futile cycles of 
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repair to facilitate completion of replication of intervening DNA while preventing activation of 
inactive/late S phase replication clusters. This minimizes ssDNA stretches, ensures maximum 
completion of DNA replication, relieving the need for fork reversal mediated fork protection leaving 
only short ssDNA stretches across from MeG lesions. (C) Progression through S phase continues 
albeit slowly and ATR-Chk1 mediated fork protection mechanisms ensure that DNA replication 
similarly completed within late S phase replication clusters.   
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Fig. 4-2. Proposed model for accelerated damage accumulation upon inhibition of ATR-
Chk1 signaling in transformed cells experiencing MMR-induced fork stalling in response 
to alkylation damage. 
ATR-Chk1 signaling coordinates origin usage to limit the number of forks experiencing MMR-
mediated futile processing at any given time. Inhibition of ATR-Chk1 signaling results in 
deregulated origin firing and premature activation of late S-phase. This would significantly 
increase the number of forks experiencing MMR-directed fork stalling simultaneously. 
Consequentially, large number of ssDNA stretches accumulate at forks stalled by MMR. As 
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ssDNA stretches exceed cellular RPA pools, RPA mediated fork protection mechanisms fail 
leading to fork breakage and replication catastrophe. Also, in the absence of ATR-directed 
regulation of DNA translocase, SMARCAL1, reversed forks undergo aberrant processing leaving 
them susceptible to structure specific endonucleases, resulting in fork breakage and double 
strand break formation.  
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response in hESCs (Desmarais, Hoffmann et al. 2012). Low levels of ATR-Chk1 activation might 
be sufficient to coordinate replication in an unperturbed S phase. But, absence of an ATR-Chk1 
replication stress response limits their ability to tolerate fork stalling (Desmarais, Hoffmann et al. 
2012). Instead, hPSCs favor elimination when exposed to genomic insults. Consequentially, we 
could discern the effects of MMR-activity on fork progression in the absence of ATR-Chk1 
signaling but without the DNA damage cross-talk offered by ATR-Chk1 inhibition. Under these 
conditions, MMR-activity in response to alkylation damage severely compromises DNA replication 
with extensive and rapid damage accumulation (Fig. 4-3). In this work, we propose that the ATR-
Chk1 signaling is crucial to mitigating the effects of MMR-induced replication stress in response 
to alkylation damage. We propose the following protection and/or compensatory mechanisms that 
might be offered by ATR-Chk1 signaling in response to MMR-induced replication stress 
conditions.  
 
Use of dormant origin firing 
Slowed progression through S-phase in MNNG-treated HeLa cells is marked by persistent 
activation of early S-phase replication clusters and delayed activation of late replicating clusters 
(Fig. 3-8C). As discussed earlier, ATR-Chk1 signaling is thought to control origin firing to mitigate 
the effects of replication stress. In cancer cell models, this signaling could promote dormant origin 
firing in the proximity of forks stalled by MMR-directed futile cycles of repair to facilitate completion 
of DNA replication (Fig. 4-1). The contribution of dormant origin firing to replication completion 
could be assessed in HeLa cells using adapted DNA fiber labelling assays (Merrick, Jackson et 
al. 2004). By labelling nascent DNA consecutively with two different nucleoside analogues, 
replication stress induced latent origins usage would yield decreased inter-origin distances. 
Alternatively, number of licensed origins could be reduced via a partial knockdown of origin 
licensing factor, MCM. As licensed origins far exceed that required during unperturbed DNA 
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replication, a decrease in origin licensing has little effect on DNA replication in HeLa cells 
(Woodward, Gohler et al. 2006, Alver, Chadha et al. 2014). Conversely, if MMR-proficient HeLa 
cells exposed to alkylation damage rely on dormant origins to rescue DNA replication, then 
decreased origin licensing would compromise global DNA replication. This could also lead to 
accelerated DNA damage accumulation and increased sensitivity to alkylation damage, like that 
observed in hESCs. Furthermore, the ability of transformed cells to coopt dormant origin firing to 
cope with replication stress would provide further evidence to support why the effects of MMR 
processing of MeG/T mismatches on global DNA replication have largely gone unnoticed.  
Interestingly, the mechanisms by which ATR-Chk1 signaling regulates origin firing remain 
unclear. Some studies suggest that dormant origin firing is independent of replication stress 
checkpoint activation. Rather, continued association of pre-replicative complex with chromatin 
near stalled forks causes firing of otherwise dormant origins (Blow and Ge 2009). Others indicate 
that ATR-targeted MCM phosphorylation near stalled forks allow these origins to evade the 
checkpoint-mediated origin suppression (Cortez, Glick et al. 2004, Yoo, Shevchenko et al. 2004). 
An understanding of the dynamics and usage of dormant origin firing in hESCs could therefore 
provide valuable insights into these complex regulatory mechanisms. DNA fiber labeling assays 
mentioned above could help inform dormant origin usage in hESCs in response to MMR-
processing of alkylation damage. The absence of decreased inter-origin distances in hESCs 
would affirm the inability to complete DNA replication between stalled forks and explain the 
decrease in global DNA replication we reported under these conditions.  
But, the inability to replicate intervening DNA could arise from the lack of excess licensed 
origins, limited origin firing factors and/or lack of ATR-Chk1 mediated activation of licensed 
dormant origins (Fig. 4-3). hESCs might license only as many origins as are required to complete 
replication in the absence or presence of low levels of replication stress. Correspondingly, 
increased origin licensing in hESCs by overexpression of origin licensing factors like Cdt1 or 
103 
 
CDC6 should reduce basal replication-stress associated damage accumulation and sensitivity to 
alkylation damage. Origin licensing in the absence of their usage in hESCs could be regarded as 
an energetically wasteful process. The shortening of origin licensing G1 phase might therefore 
allude to an evolutionary mechanism to restrict the ability of hPSCs to tolerate replication stress 
(Becker, Ghule et al. 2006). Indeed, lengthening the origin licensing G1 phase in mESCs 
decreases basal levels of replication stress (Ahuja, Jodkowska et al. 2016). This study proposed 
that longer G1 phases allowed for adequate resolution of DNA damage. However, they did not 
assess increased origin licensing under these conditions. Also, decreasing origin licensing in 
hESCs promoted differentiation (Matson, Dumitru et al. 2017). As hESCs exposed to genotoxic 
stress also undergo differentiation, it could suggest that origin licensing in hESCs is limited and a 
decrease in licensing factors increases endogenous stress. Under these conditions, low levels of 
stress might prompt differentiation to promote survival and tissue homeostasis while preventing 
hPSCs experiencing even low perturbations to fork progression from accumulating DNA damage 
that could affect normal tissue functioning. Also, increased expression of origin licensing factors 
accompanies transformation (Blow and Gillespie 2008, Zimmerman, Jones et al. 2013). 
Therefore, by assessing how levels of chromatin-loaded MCM in hESCs correlate with that found 
in cancer cells, increased origin licensing could be indicative of oncogenic transformation. 
Conversely, the ability of overexpression of the origin firing factor, CDC45, to reduce both 
endogenous and replication-stress associated DNA damage accumulation would suggest that 
origin firing and not licensing is limiting in hPSCs. More interestingly, as hESCs do not activate 
ATR-Chk1 checkpoint signaling, the ability of these mechanisms to rescue global DNA replication 
would indicate that regulation of origin firing in response to fork stalling is independent of 
checkpoint control. However, the inability of these mechanisms to counteract the effects of 
replication stress associated damage would suggest that ATR-Chk1 signaling is important for 
activation of dormant firing. If so, replication stress induced upregulation of ATR-Chk1 signaling 
upon oncogenic transformation could directly promote increased origin firing to mitigate 
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accumulation of replication stress associated damage. Additionally, it would suggest that 
increased origin usage in cancer cells is an ATR-Chk1 induced adaptation to oncogenic 
replication stress.  
 
RPA mediated protection of ssDNA stretches  
In our work we observed that inhibition of ATR kinase accelerated damage accumulation 
and fork collapse in MMR-proficient HeLa cells treated with MNNG. Additionally, the increase in 
chromatin loading of RPA in response to alkylation damage in transformed cells expressing a 
kinase dead mutant of ATR would suggest an ATR-mediated control on ssDNA accumulation 
(Stojic, Mojas et al. 2004). These point to a model wherein ATR-Chk1 signaling limits ssDNA 
accumulation and protects forks stalled by MMR activity in response to alkylation damage (Fig. 
4-1). Indeed, intra-S phase checkpoint mediated coordinated origin usage has been implicated in 
limiting damage accumulation at stalled forks. Particularly, as the helicase uncouples from DNA 
polymerase, the continued unwinding of parental DNA generates large ssDNA tracts (Byun, 
Pacek et al. 2005). These regions are coated and protected by the ssDNA binding protein, RPA, 
until replication is completed by replication initiation from a nearby dormant origin. Concurrently, 
checkpoint mediated suppression of late origin firing ensures that number of stalled forks are low 
and ssDNA stretches are kept at a minimum, facilitating cell survival (Toledo, Altmeyer et al. 
2013). However, in the absence of functional ATR-Chk1 signaling deregulated origin firing leads 
to formation of ssDNA that exceed cellular RPA pools. Lack of protection of these ssDNA regions 
leaves them prone to breakage causing fork collapse (Toledo, Altmeyer et al. 2013).  
As per this model, the intra-S phase checkpoint could limit the number of forks 
experiencing MMR-mediated futile processing at any given time thereby maintaining low levels of 
ssDNA stretches that are protected by RPA (Fig. 4-1). Thus, MMR-proficient cancer cells 
complete DNA replication leaving short unreplicated gaps observed in electron micrographs that 
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correspond to the remnants of excision reactions across from MeG lesions (Mojas, Lopes et al. 
2007). Conversely, deregulated origin firing upon ATR-Chk1 inhibition in transformed cells would 
significantly increase the number of forks experiencing MMR-directed fork stalling simultaneously 
(Fig. 4-2). Subsequently, cellular RPA pools capable of fork protection would be exhausted, 
leading to fork breakage. To this end, increasing or decreasing cellular RPA pools should delay 
or accelerate collapse of forks stalled by MMR-directed futile processing at multiple MeG/T lesions 
in cancer cells respectively.  
Furthermore, we propose an alternative form of deregulated origin firing in hESCs in 
response to MMR-induced replication stress. In this model, MMR-directed futile cycles disrupt 
fork progression, uncoupling the helicase from the DNA polymerase creating ssDNA stretches 
(Byun, Pacek et al. 2005). However, the inability to complete DNA replication from adjacent 
origins would leave these large stretches of ssDNA unresolved (Fig. 4-3) (Blow, Ge et al. 2011). 
Additionally, without activation of an intra-S phase checkpoint late origin firing would continue 
uninterrupted (Ge and Blow 2010). Under these conditions, the continued accumulation of large 
ssDNA stretches would exhaust cellular RPA pools leading to fork collapse. Also, increasing or 
decreasing cellular RPA pools should delay or accelerate collapse of forks stalled by MMR-
directed futile processing in hESCs respectively.  
 
Fork reversal and processing 
Fork reversal is important for protection and stabilization of stalled forks. Yet, electron 
micrographs of forks isolated from MMR-proficient transformed cells exposed to alkylation 
damage show no evidence of fork reversal (Mojas, Lopes et al. 2007). This suggested that MMR 
activity must be executed behind the ongoing fork and has no effect on fork progression. Firing of 
dormant origins under these conditions would not be required. MMR activity would be expected 
to create ssDNA gaps of similar length in both hPSCs and transformed cells. Additionally, as 
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these cell systems express equal amounts of cellular RPA, one would predict that concurrently 
the RPA-mediated protection would be similar (Fig. 2-8C). It is therefore hard to comprehend why 
the absence of ATR-Chk1 signaling would lead to accelerated damage accumulation and 
sensitivity to alkylating agents in both these model systems.  
Herein, we suggest that MMR-induced fork stalling does cause fork reversal (Fig 4-1). 
However, ATR-Chk1 signaling mediated completion of DNA replication by a converging fork 
relieves the need for protection of ssDNA through the formation of a chicken foot structure. 
Subsequently, the inability to faithfully replicate across MeG lesions leaves only small ssDNA gaps 
at the end of the first S phase (Mojas, Lopes et al. 2007). Additionally, as ATR signaling prevents 
aberrant fork processing from generating structures that are susceptible to SLX4-dependent 
endonucleases, compromised fork integrity in the absence of ATR signaling would also explain 
accelerated damage accumulation and sensitivity to alkylating agents in both these model 
systems (Fig. 4-2) (Couch, Bansbach et al. 2013).  
Interestingly, mESCs experience increased frequency of fork reversal in response to 
higher levels of endogenous replication stress compared to their differentiated counterparts 
(Ahuja, Jodkowska et al. 2016). Similar signs of increased endogenous replication stress have 
also been reported in hESCs. Thus, in the absence of external stimuli low levels of basal ATR 
activation might suffice to regulate SMARCAL1 activity at the limited number of forks experiencing 
replication stress, ensuring their appropriate fork processing. Conversely in presence of 
replication stress inducers, these low levels of ATR activation might not suffice/fail to regulate 
SMARCAL1 directed remodeling at rapidly accumulating stalled forks (Fig. 4-3). As a result, 
MMR-induced replication stress would be evidenced by increased fork reversal in hESCs exposed 
to alkylation damage. Similarly, such MMR-mediated processing in cancer cells in the absence of 
ATR signaling would also lead to increased frequency of fork reversal. Additionally, fork collapse 
and increased sensitivity resulting from deregulated processing at these forks would be alleviated 
107 
 
by knockdown of either the DNA translocase SMARCAL1 involved in fork processing or SLX4, 
the structural subunit of structure-specific endonucleases.   
Evidence supporting fork reversal mediated protection of forks stalled by MMR could 
provide important insights into the mechanism of MMR. In vitro, strand discrimination is always 
directed by a nick on one strand that serves as an entry site for MMR-mediated excision by an 
exonuclease (Holmes, Clark et al. 1990, Thomas, Roberts et al. 1991). However, the source of 
these discontinuities on replicating cellular DNA has remained a long-standing question in the 
field. The ends of the Okazaki fragments in the lagging strand and the single 3’ end of the leading 
strand would make for the most consistent potential entry sites for MMR-associated exonuclease 
loading. At forks encountering MeG lesions, repeated mismatch generation and MMR-directed 
excision from these sites could require pausing of replication machinery to allow the repair 
process to occur. Even so, excision reactions on the lagging strand may not have lasting 
consequences on fork progression as replication could be rescued by the priming of new Okazaki 
fragments. On the leading strand however, the effect of futile cycles of repair on the fork may be 
much more severe. Interestingly, SMARCAL1 catalyzes reversal of stalled forks with leading 
strand gaps created upon uncoupling of the replicative helicase and leading-strand polymerase 
(Betous, Couch et al. 2013). Therefore, an alleviation in fork collapse and sensitivity to alkylation 
damage caused by a lack of ATR-Chk1 signaling in either transformed cells or hESCs upon 
knockdown of SMARCAL1 would provide evidence supporting the role of MMR-mediated 
daughter strand excision reactions in compromising progression of the leading strand 
polymerase. Furthermore, with the entry site for the 5’-3’ directed exonuclease 1 on the leading 
strand still being a point of contention, it would be interesting to see if generation of nicks 5’ to the 
MeG lesions by PMS2’s endonuclease activity changes the dynamic of fork reversal, ssDNA 
accumulation, fork collapse and sensitivity to alkylation damage in the absence of ATR-Chk1 
signaling in transformed cells and hESCs. These results would provide more direct insights into  
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Fig. 4-3. Proposed model for accelerated damage accumulation in the absence of ATR-
Chk1 replication stress response in hESCs experiencing MMR-induced fork stalling in 
response to alkylation damage. 
(A) Iterative cycles of MMR-directed processing at forks encountering MeG lesions on the template 
strand disrupts fork progression. (B) MMR-induced fork stalling results in uncoupling of DNA 
helicase from the replication machinery resulting in ssDNA stretches. RPA protects ssDNA 
generated at stalled forks preventing fork breakage. RPA bound to ssDNA recruits DNA 
translocase, SMARCAL1, initiating fork reversal mediated fork protection. In the absence of ATR-
mediated regulation of SMARCAL1, reversed forks undergo aberrant fork processing leaving 
them susceptible to structure specific endonucleases, resulting in fork breakage and double 
strand break formation. However, in the absence of dormant origin firing in the proximity of forks 
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stalled by MMR-directed futile cycles of repair intervening DNA remains unreplicated. (C) 
Progression through S phase continues, and DNA replication is initiated within late S phase 
replication clusters. As the number of forks experiencing MMR-directed fork stalling increases, 
the accumulating levels of ssDNA increase. Once, ssDNA stretches exceed cellular RPA pools, 
RPA mediated fork protection mechanisms fail leading to fork breakage and replication 
catastrophe cellular RPA pools. Additionally, as aberrant remodeling of stalled forks continues in 
the absence of ATR regulation, forks collapse and double strand breaks accumulate.  
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how MMR directs excision on the leading strand particularly at forks encountering alkylation 
damage.  
 
VII. MMR-INDUCED REPLICATION STRESS: POTENCY TO CHEMOTHERAPEUTIC DNA ALKYLATING 
AGENTS  
 
Understanding the protective role of ATR-Chk1 signaling in response to MMR-induced replication 
stress conditions has provided important insights into the mechanistic understanding of MMR 
activity at the fork. However, this work also has crucial implications from a therapeutic stand point. 
Early work in transformed cells by other groups have recurrently noted an upregulation and 
increased dependence on ATR-Chk1 signaling. Since, ATR and Chk1 kinases have been deemed 
crucial for protecting transformed cells from replication stress accompanying oncogenic 
transformation. As a result, inhibition of ATR-Chk1 signaling has made for a viable and actively 
sought-after avenue for selectively sensitizing cancer cells either alone or in conjunction with 
replication stress inducing chemotherapeutic agents (Zabludoff, Deng et al. 2008, Ma, Janetka et 
al. 2011, Toledo, Murga et al. 2011, Foote, Lau et al. 2015). Our work suggests that these 
mechanisms could extended to alkylation-based chemotherapeutics in the clinic used to treat 
MMR-proficient cancers. Along these lines, in the two transformed cell systems we tested, HeLa 
cells and the osteosarcoma cell line U2OS, we observed a MMR-dependent increase in sensitivity 
to alkylation damage upon ATR inhibition (Fig. 4-4). As an extension to these studies it would be 
interesting to understand if replication stress induced checkpoint activation is a characteristic of 
cancer stem cells and/or observed in adult stem cell systems. Therefore, by classifying the MMR-
directed response to alkylation damage as a replication stress inducer our work provides crucial 
and exciting avenues for therapeutic intervention towards increasing sensitivity to 
chemotherapeutic DNA alkylating agents. 
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Fig. 4-4. Inhibition of ATR-Chk1 signaling in the first S phase increases sensitivity of U2OS 
cells to alkylation damage.  
Immunostaining for cleaved-caspase-3 at 72 h in U2OS cells treated with 2 μM MNNG for the first 
16 h in the presence or absence of ATRi (10 μM). 
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VIII. MMR-INDUCED REPLICATION STRESS: SELECTION PRESSURES FOR LOSS OF MMR, SURVIVAL AND 
TUMORIGENESIS 
  
 MMR is critical for the maintenance of genomic stability. Although individuals with Lynch 
syndrome are initially heterozygous for a mutant MMR gene, a spontaneous mutation or loss of 
heterozygosity event at the wild type allele confers complete loss of MMR function (Lynch, Lynch 
et al. 2009). Also, 10-40% of spontaneously arising colorectal and other tumor types lose MMR 
function (Heinen 2014). But delineating the physiological factors that drive cells to lose MMR 
function early in tumorigenesis poses a significant challenge. Furthermore, as DNA polymerase 
errors go uncorrected, the subsequent increased mutation burden accompanying MMR loss is 
ascribed to promote tumorigenesis (Loeb 1991, Kat, Thilly et al. 1993, Fishel, Lescoe et al. 
1994). Conventionally, loss of MMR has been speculated to promote tumorigenesis via this 
indirect mechanism. 
 Yet, unexpectedly, in our day-to-day culturing we observed that MSH2 knockout hESCs 
consistently outgrew MMR proficient hESCs. Upon quantitation, it was noted that within five 
days three different MSH2-/- hESCs achieved cell densities that were two to four-fold higher 
compared to MMR proficient wildtype hESCs (Fig. 4-5A) (Madden-Hennessey, unpublished 
results). Also, MSH2 loss in hESCs significantly reduced the basal number of γH2AX damage 
foci, which are proposed to arise from the increased levels of endogenous replication stress 
inherent to embryonic stem cells (Fig. 4-5B) (Ahuja, Jodkowska et al. 2016). These results would 
indicate that MMR activity somehow induces DNA damage and/or replication stress in cultured 
hESCs.  
 Considering our newly identified role of MMR directed processing as a replication stress 
inducer, we would predict that DNA lesions created by normal cellular metabolism and/or 
environmental factors engage MMR. Depending on the relative abundance of these lesions, 
MMR could elicit replication stress induced cytotoxicity and/or slowed cell cycle progression. 
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Fig. 4-5. Loss of MMR activity in hESCs decreases basal damage accumulation and 
increases cell growth   
(A) WT, KO1, KO2 and KO3 hESCs seeded at equal cell density were assessed for 
average viable cell density over five consecutive days using Trypan blue exclusion 
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method. (B) Immunostaining for DNA damage marker γH2AX in WT, KO1, KO2 and KO3 
hESCs in culture.  
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Furthermore, stem cells experiencing such replication stress likely undergo apoptosis in part 
due to the intense pressure on these cells to maintain genomic stability and normal physiology. 
Thus, environmental stresses that promote formation of lesions responsible for activating MMR-
directed replication stress induced cytotoxicity would pose a strong selection pressure for loss 
of MMR activity. The subsequent loss of functional MMR would directly result in the acquisition 
of a survival advantage over MMR-proficient cells (Fig. 4-6). In this manner, we propose that 
loss of functional MMR directly promotes early stages of tumorigenesis wherein the subsequent 
accumulation of mutations within tumor suppressor genes and oncogenes would further 
exacerbate the growth advantage to promote cancer progression. Also, studies ascertaining the 
exact nature and sources of these stresses and lesions would help inform cancer prevention 
measures especially in Lynch syndrome patients. Herein, we describe some putative stresses 
that might pose strong selection pressures to lose MMR function:  
 
Environmental pressures 
 The MMR-dependent increase in basal damage accumulation in hESCs would suggest 
that lesions capable of engaging MMR are generated either as a byproduct of cellular 
metabolism or stresses inherent to culturing hESCs. The outcomes of the ensuing MMR activity 
on hESCs however remain unclear. Understanding if MMR loss reduces background cell death 
and/or shortens cell cycle duration of hESCs in culture could help ascertain the nature of the 
advantage offered by loss of MMR. The resulting survival and/or growth advantage could help 
ascertain how cells selected for loss of MMR function promote initial stages of tumorigenesis in 
an otherwise MMR-proficient tissue. Determining the nature, sources and MMR-directed 
responses to these lesions could therefore provide important insights into lesions and more 
importantly, selection pressures, most likely to arise within the physiological environment of 
tissues.  
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 Oxidative stress resulting from cellular metabolism could be one such source of lesions 
that is capable of engaging MMR (DeWeese, Shipman et al. 1998, Hanawalt 1998, Barnes and 
Lindahl 2004). Particularly, 8-oxoguanine (8-oxoG) lesions created by oxidation of guanine 
resides within DNA mispair with adenine during DNA replication (Shibutani, Takeshita et al. 
1991). These 8-oxoG/A lesions are recognized by MMR proteins and could elicit MMR directed 
repair like that observed in response to MeG/T lesions (Ni, Marsischky et al. 1999, Mazurek, 
Berardini et al. 2002). In a similar futile cycle response, resulting MMR activity would be 
predicted to induce replication stress, which in hESCs is cytotoxic (Fig. 4-6). Interestingly, 
mESCs heterozygous or homologous for MMR loss show decreased sensitivity to low doses of 
oxidative damage (DeWeese, Shipman et al. 1998). Furthermore, this is accompanied by 
increased accumulation of mutagenic oxidative lesions. On these lines it would be interesting to 
understand how MMR responds to low doses of 8-oxoguanine (8-oxoG) lesions. Work in this 
direction could help ascertain if environments prolific in oxidative stresses would pose a strong 
selection pressure for loss of MMR. On similar lines, our work herein would suggest that 
environments rampant with alkylation damage would pose a strong pressure to lose MMR 
activity (Fig. 4-6). Diet and metabolic byproducts of colonic bacterial populations are already 
known sources of N-nitroso compounds (Povey, Hall et al. 2000). Colonic stem cells resident to 
such environments would have an increased propensity to lose MMR function to bypass MMR-
dependent cytotoxicity. Studies targeting an understanding of these response in hESCs and 
subsequently in tissue specific stem cells, like colonic stem cells could help redefine MMR genes 
as classical tumor suppressors and guide cancer prevention methods, particularly in relation to 
dietary intake.  
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Pressures driven by other somatic mutations 
 Thus far we have largely described MMR-induced futile repair cycles initiated by 
preferential mispairing of modified bases during DNA replication as a potent replication stress 
inducer. The coordination between MMR-directed repair and fork movement would have the 
repeated engagement of MMR-directed processing be disruptive for fork progression. Therefore, 
conditions wherein MMR-activity is repeatedly engaged due to frequent base mispairing could 
also affect fork progression (Fig 4-6). While these might not cause a potent blockade to fork 
progression, the affected fork movement could elicit cytotoxicity especially when the frequency 
of introducing DNA replication errors is particularly high. Namely, oncogenic transformation is 
associated with high levels of replication stress and exhaustion of nucleotide pools (Bartkova, 
Rezaei et al. 2006, Di Micco, Fumagalli et al. 2006, Bester, Roniger et al. 2011, Venkitaraman 
2011). In the absence of sufficient nucleotide pools, progression of DNA polymerase is affected. 
Additionally, this could increase frequency of nucleotide misincorporations. Consequentially, it 
could result in increased canonical MMR activity, which would further impede fork progression. 
As misincorporation rate increases, fork progression would be increasingly affected leading to 
apoptotic induction in hESCs and tissue-specific stem cells. In this manner, acquisition of 
oncogenic mutations could place an increased selection pressure to lose MMR to promote 
oncogenic transformation (Fig. 4-6).  
 Interestingly, sporadic colon cancers with the oncogenic BRAF-V600E mutation frequently 
also have loss of MLH1 protein expression resulting from hypermethylation of the MLH1 
promoter (Deng, Bell et al. 2004). Additionally, whether loss of MLH1 precedes acquisition of 
the oncogenic BRAF mutation has been a major point of contention in the field. Our hypothesis 
suggests that acquisition of mutant BRAF in the initial stages of oncogenic transformation could 
drive increased replication rates, nucleotide pool depletion and increased nucleotide 
misincorporation. The resulting MMR-induced replication stress would however suppress  
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Fig. 4-6. MMR-induced replication stress as a selection pressure for loss of MMR function 
in the acquisition of a direct survival advantage during early transformation. 
Environmental stresses like reactive oxygen species or N-nitoso compounds generate DNA 
lesions that are preferentially paired with the wrong nucleotide during DNA replication. Also, 
depletion of nucleotide pools caused by increased proliferation during oncogenic transformation 
or acquisition of other somatic mutations that affect DNA replication fidelity to introduce DNA 
mismatches. Increased MMR-activity at sites of nucleotide misincoporations can affect fork 
progression and induce replication stress. These perturbations to fork progression could trigger 
apoptosis, placing an increased pressure to lose MMR function. Under these conditions, loss of 
MMR function would result in a direct survival advantage and clonal expansion of MMR-/- cells to 
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initiate transformation. The increased in mutation load following loss of MMR function would 
promote and accelerate cancer progression.  
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expansion of this cellular subset creating a strong selection pressure to lose MMR activity 
leading to MLH1 promoter hypermethylation and loss of MLH1 protein expression (Kane, Loda 
et al. 1997, Veigl, Kasturi et al. 1998, Deng, Bell et al. 2004). Similarly, this activity also would 
explain why tumor cells carrying an inactivating mutation in the proofreading domain of DNA 
polymerase ε also lose MMR function (Yoshida, Miyashita et al. 2011). Studies in this direction 
would ascertain increased MMR activity to be a stringent bottleneck to early oncogenic 
transformation and understand the role of different transforming principles in creating strong 
selection pressures for MMR loss.  
 
IX. SUMMARY 
 
 In conclusion, by ascertaining the effects of MMR-dependent MeG/T mismatch recognition 
on the first S phase our work shows that MMR-mediated processing of alkylation damage affects 
fork progression. Activation of ATR-Chk1 signaling is required to mitigate ensuing replication 
stress, damage accumulation and facilitate completion of DNA replication. Taken together, we 
define the MMR-directed response to alkylation damage as a replication stress inducer. This 
work changes how we view this post-replicative repair pathway, suggesting a coordination 
between MMR activity and the replication fork. Furthermore, understanding MMR activity in the 
context of a replication stress inducer has far reaching implications for the mechanism of MMR, 
early tumorigenesis, cancer prevention and chemotherapeutics.      
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